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ENGLISH SUMMARY 
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the 
gastrointestinal tract, characterized by an excessive immune response to an unknown 
microbial trigger, in genetically susceptible hosts. The incidence and prevalence of 
IBD is on the rise on every continent, and currently affects approximately 5 million 
people worldwide. The current understanding is that dysbiosis of the gut microbiota 
plays an important part in development and maintenance of epithelial inflammation, 
and microorganisms with virulent capacities are involved in this process.  
Campylobacter concisus is a genetically diverse, oral bacterium that has been 
associated to gastrointestinal diseases such as prolonged diarrhea, Barrett’s 
esophagus and IBD. Previous studies have detected higher amounts of C. concisus 
DNA from IBD patients, but cultivation has been sparse. In-vitro studies on the 
pathogenic properties of this bacterium has shown that it is capable of epithelial cell 
invasion and disassembly, and can facilitate an increased inflammatory response by 
inducing cytokine production.  
The aim of our studies was to ascertain the prevalence of viable C. concisus from the 
gastrointestinal tract of patients with IBD and healthy controls, and to compare 
isolates between groups as well as from different sites in the same individual. Over a 
period of two years, we systematically collected saliva, stool and mucosal biopsies 
from 57 IBD patients, 28 healthy controls and two patients with persistent diarrhea, 
to assess the rate of viable C. concisus. By implementing a novel cultivation method 
(the “Aalborg two-step method”), we found that there was a high rate of C. concisus 
from all sample types, in all three groups. However, abundance was highest for the 
subgroup of IBD patients with the most clinical symptoms, indicating that increased 
abundance of C. concisus may be implicated in disease. Whole-genome sequencing 
was used for genetic comparison of 104 isolates. By Multi-locus Sequence Typing 
(MLST) of housekeeping genes, 16S rRNA and 23S rRNA sequences, we found that 
isolates clustered into two genomospecies, with no correlation to clinical 
presentation. It was apparent, that individuals were colonized with several different 
C. concisus strains, even in the same anatomic location. We also looked for certain
genes associated to pathogenicity and found that these were present in isolates from
all groups and from all locations, again with no correlation to clinical presentation.
In conclusion, colonization with C. concisus is common and not restricted to the oral 
cavity or only related to gastrointestinal disease. An explanation could be, that C. 
concisus is a pathobiont – a commensal bacteria with virulent properties that are only 
expressed under certain conditions, such as dysbiosis of the microbiota in an 
inflammatory state. Experimental studies are needed to verify that hypothesis.  
DANSK RESUME 
Inflammatorisk tarmsygdom (Inflammatory Bowel Disease, IBD) er en kronisk 
inflammationstilstand i tarmen. Ætiologien er ukendt, men menes at være et 
uhensigtsmæssigt immunrespons udløst af en eller flere mikroorganismer, hos 
genetisk prædisponerede individer. Incidencen og prævalensen af IBD er stigende, 
således er der på verdensplan ca. 5 millioner afficerede mennesker.  Det er vist, at en 
uhensigtsmæssig sammensætning af bakterier i tarmen (dysbiose), spiller en vigtig 
rolle i udviklingen og vedligeholdelsen af inflammationstilstanden, og at bestemte 
mikroorganismer med patogene egenskaber kan være medvirkende i denne proces. 
Campylobacter concisus er en heterogen bakterie, der tidligere har været associeret 
til langvarig diarré, Barrett’s øsofagus og senest, IBD.  Tidligere studier har fundet 
en højere forekomst af C. concisus DNA i prøver fra patienter med IBD 
sammenlignet med raske, men dyrkning har været sparsom. In-vitro studier har vist, 
at C. concisus har flere patogene egenskaber, med invasion og ødelæggelse af 
epitelceller og efterfølgende opregulering af det inflammatoriske respons. 
Formålet med vores studier var, at undersøge prævalensen af levedygtige C. concisus 
hos patienter med IBD og raske kontroller og at sammenligne isolater fra de 
forskellige grupper, samt fra forskellige anatomiske lokalisationer hos den enkelte. I 
en periode på to år, indsamlede vi spyt og afføringsprøver samt tarmbiopsier fra 57 
IBD patienter, 28 raske kontroller og to patienter med persisterende diarré. Vi 
beskrev en ny metode (”Aalborg two-step method”) til dyrkning af biopsier, og fandt 
at antallet af personer med levedygtige C. concisus i tarmen var høj, hos både 
patienter med IBD og raske kontroller. IBD patienterne med de sværeste symptomer 
havde en højere forekomst af C. concisus sammenlignet med de øvrige grupper, 
hvilket kunne tyde på, at en større mængde bakterier kunne være associeret til 
sygdom. Et-hundrede-og-fire isolater blev analyseret ved hel-genom-sekventering og 
efterfølgende typning af forskellige husholdningsgener, 16S rRNA og 23S rRNA 
sekvenser. Isolaterne fordelte sig i to genomospecies, der ikke viste association til 
den kliniske tilstand. Det var tydeligt, at individer kan koloniseres af flere forskellige 
C. concisus stammer, selv i samme lokalisation. Vi undersøgte genomerne for
potentielle virulens-gener, tidligere beskrevet for C. concisus. Her var der ligeledes
ingen forskel mellem grupperne og heller ingen association til klinisk præsentation.
Som konklusion fandt vi, at kolonisering med C. concisus er almindeligt, og ikke 
begrænset til mundhulen eller kun associeret til gastrointestinal sygdom.  En 
forklaring kunne være, at C. concisus er en “pathobiont” – en naturligt 
forekommende bakterie, der kun under de rette omstændigheder kan udvise patogene 
egenskaber, som kan medvirke til inflammation. Eksperimentelle studier er 
nødvendige, for at belyse det nærmere.  
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PREFACE   
“The real journey of discovery consists not of seeking new 
landscapes, but in having new eyes.”  
- Marcel Proust.  
 
 
Inflammatory bowel disease (IBD) is a chronic, relapsing condition that affects an 
estimated 2.5 million people in Europe with a steadily rising prevalence all over the 
world. Repeated periods of medical and surgical treatment in affected individuals can 
have detrimental effects on their quality of life and ability to work, conjointly being a 
substantial socioeconomic burden. The etiology of IBD is widely accepted as being 
an exaggerated immune response in genetically susceptible individuals, and the 
trigger for this inflammatory overreaction is suggested to be dysbiosis of the intestinal 
flora, in which pathogenic bacteria can thrive.  
 
Campylobacter concisus is an emerging pathogen of the gastrointestinal tract that was 
originally associated to periodontal disease, and since, premalignant lesions of the 
esophagus and prolonged diarrhea. While studies have found an association to IBD, 
coinciding findings in healthy individuals continues to question and contradict a 
possible correlation. Recent molecular studies on available C. concisus isolates have 
expanded our understanding of the vast genetic diversity that this bacterial species 
represents, and it is clear that some subtypes harbor pathogenic potentials. However, 
a sparse number of isolates retrieved from the gut mucosa of IBD patients and healthy 
individuals have limited the possibility of substantializing this further. 
 
With the expansion of advanced molecular diagnostics such as whole-genome 
sequencing (WGS) the possibilities for genetic comparison of bacterial isolates have 
improved tremendously. Over a period of two years, we systematically collected C. 
concisus isolates from saliva, stool and mucosal biopsies of patients with IBD and 
healthy individuals, in order to perform and optimize cultivation procedures and use 
whole-genome sequencing methods for isolate comparison. Our hypothesis was that 
specific pathogenic strains of C. concisus are involved in the inflammatory state of 
gastrointestinal disease.  
This project was carried out in collaboration between the Departments of Infectious 
Diseases, Clinical Microbiology and Gastrointestinal Surgery at Aalborg University 
Hospital, Denmark, and the Milner Center for Evolution, Department of Biology and 
Biochemistry at Bath University, United Kingdom.   
 
13 
This thesis is based on the following papers:  
1: Karina Frahm Kirk, Hans Linde Nielsen, Ole Thorlacius-Ussing, Henrik Nielsen 
Optimized cultivation of Campylobacter concisus from gut mucosal biopsies in 
inflammatory bowel disease Gut Pathogens 2016;1:8-27 
 
2: Karina Frahm Kirk, Hans Linde Nielsen, Guillaume Meric, Ben Pascoe, Samuel K. 
Sheppard, Ole Thorlacius-Ussing, Henrik Nielsen 
Comparing Campylobacter concisus strains from saliva, faeces and gut mucosal 
biopsies in inflammatory bowel disease by multi-locus sequence typing using 
whole genome sequence data. Draft 
3: Karina Frahm Kirk, Hans Linde Nielsen, Guillaume Meric, Ben Pascoe, Samuel K. 
Sheppard, Ole Thorlacius-Ussing, Henrik Nielsen 
Virulence-associated genes in Campylobacter concisus isolates from patients with 
inflammatory bowel disease and healthy controls in Denmark. Draft 

15 
CHAPTER 1. BACKGROUND 
1.1. The gut mucosa and intestinal microbiota 
Intestinal homeostasis depends on complex interactions between commensal gut 
microbes and epithelial, innate and adaptive immune cells in the gut mucosa. The gut 
epithelium is the subject of continuous, rapid renewal that occurs without disruption 
of the functional integrity and permeability.1 Remarkably, it consists of just one layer 
of epithelial cells organized into crypts and villi to allow for nutrient absorption as 
well as water and electrolyte transport. The cells of the epithelium are highly 
specialized and differentiated to maintain the many physiological functions, and serve 
as a barrier to pathological intrusions. The most abundant cell type is the absorptive 
enterocyte, which is adapted for digestive functions. Goblet cells reside throughout 
the small and large intestine and produce mucus, which is a key element in the barrier 
function, as well as a source of nutrients for saccharolytic bacteria. Alongside 
microfold cells, they are also involved in the transport of luminal antigens and bacteria 
across the epithelial barrier to dendritic cells.2 In the small intestine, Paneth cells 
synthesize and secrete antimicrobial proteins (AMPs) such as lysozyme and 
defensins.3 Peyers patches and lymphoid follicles exist imbedded in, and immediately 
below the epithelial layer in the lamina propria, where macrophages, lymphocytes and 
other cells of the immune system reside in abundance, for prompt reaction to breach 
of barrier integrity.4 Enterocyte cell adhesion is mediated by tight junctions (TJ), 
adherens junctions and desmosomes; protein structures located between enterocytes. 
Tight junctions provide a barrier between the gut lumen and the basal membrane, and 
prevent paracellular passage of fluids, electrolytes and other molecules and are a 
possible site for functional disruption by bacteria. Cells in the Peyers patches 
contribute to maintenance of microbial tolerance, by continuously presenting 
microbes to cells of the adapted immune system.1 Dendritic cells present microbial 
peptides to T-cells, resulting in differentiation into regulatory T cells (Treg) that 
produce Il-10, a cytokine with anti-inflammatory properties (Figure 1). Neutrophils 
omit bacterial killing by three mechanisms: phagocytosis, degranulation and later 
NETosis, a form of self-destruction with expansion of chromatin structures and 
nucleic proteins with antibacterial properties.3 
The composition of microorganisms that reside the human gastrointestinal tract is 
referred to as the intestinal “microbiota” – now recognized as a key player in a 
magnitude of different illnesses, not only limited to gastrointestinal disease.5 The 
volume of bacterial mass increases in the lower intestines, and the distal gut is 
estimated to harbor up to 1012 organisms per gram of luminal content.1 This complex 
ecosystem is comprised mostly of bacteria – in the healthy gut dominated by the phyla 
Firmicutes and Bacteroidetes, whereas Proteobacteria are less dominant under 
healthy circumstances.6 The combined genomes of bacterial cells in the intestine is 
known as the “microbiome”, and impressive worldwide projects have contributed to 
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our understanding of the intestinal microbiome over time, in both health and disease.7, 
8  The composition of the microbiota is different for every individual and is influenced 
by both genetic and environmental exposures, resulting in a complex interaction 
between microbes and host cells throughout life.9-11 The first colonization of humans 
occurs during birth and breastfeeding. In the first year of life, the composition of the 
intestinal microbiota is simple – at about 1-2 years of age, it stabilizes and becomes 
more diverse, and in preadolescence, it starts to resemble the adult microbiota in 
diversity, but with distinct microbial communities.12, 13 In a healthy gut, the 
microbiome contributes to immune homeostasis, physiological processes and nutrient 
supply, but perturbations from different factors can alter this homeostasis, resulting in 
dysbiosis, metabolic disease and inflammatory disorders.11 
 
Figure 1: The cells of the gut epithelium invoved in barrier protection and immune response 
to pathogenic bacteria. Reprinted by permission from Macmillan Publishers Ltd., from Cho 
JH, Nat Rev Immunol. 2008 Jun;8:458-66 
Studies on faecal samples from mono- and dizygotic twins and their family members 
have shown that the highest degree of similarity is found in samples derived from the 
same individual, and that phylotype similarity is higher between individuals in the 
same family as opposed to individuals from different families.1 Apart from genetic 
factors, the gut microbiota is influenced by environmental factors, such as exercise 
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and dietary habits,14 and even short-term dietary modifications can alter the microbial 
composition.15 The gut microbiota may be divided into “mucosa-associated” and 
“lumen-associated” categories according to anatomical location – the latter may be 
more unstable, or subject to changes in relation to environmental influences over 
time.10 Chiodini and colleagues examined microbial populations from luminal, 
mucosal and submucosal samples, and found that mucosa-associated populations and 
submucosal populations are distinct and may have independent associations to 
intestinal disease.16 
Studies on the gut microbiota in inflammatory bowel disease have led to a realization 
that rather than a single organism, the gut microbiota as a whole may be altered, and 
that this dysbiosis of microbial communities can be explained by interactions between 
different species in different environmental contexts.17-20 Pathobionts are organisms 
that are generally benign, but have the ability to exert pathogenic effects under the 
right circumstances, which usually involves a disruption of the normal gut-microbe 
homeostasis. Such organisms could therefore be key players in a prolonged 
inflammatory response in a dysbiotic environment unless homeostasis is restored.17 
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1.2. Campylobacter  
The genus Campylobacter belongs to the epsilon class of Proteobacteria in the order 
of Campylobacterales that includes the Campylobacteraceae and Helicobacteracea 
families. The genera are gram-negative, non-saccharolytic bacteria with microaerobic 
growth requirements, curved or spiral-shaped and non-spore-forming. They are 0.2 to 
0.8 µm wide and 0.5 to 5 µm long and typically motile, with a corkscrew-like 
movement due to a singular flagellum at one or both ends. Currently, the genus 
consists of 26 species, two provisional species and nine subspecies.21 They are diverse 
in clinical presentations and microbiological features, and at least 17 species have 
been associated to human disease.22 Another feature of the Campylobacter genus is 
that they have small genomes (1.6-2.0 Mb) and can establish long-term associations 
with their host.23 
 
The most widely studies species are Campylobacter jejuni and Campylobacter coli, 
which are known to cause severe gastroenteritis under the right circumstances and 
continue to be the leading cause of bacterial gastroenteritis worldwide. Gastroenteritis 
from C. jejuni represents a spectrum from mild to severe disease, but is most often 
self-limiting. Oral replacement of fluid and electrolytes is the primary therapeutic aim, 
while hospitalization and antibiotics are seldom required.24 Reservoirs include 
poultry, and other animals, as well as water sources in farm environments. Diarrhea 
due to Campylobacter infection (campylobacteriosis) is therefore most commonly 
associated to consumption of under-cooked poultry that has been contaminated during 
processing.25 Post-infectious complications such as recurrent abdominal pain, reactive 
arthritis and Guillain-Barré syndrome (GBS) have also been described.26 
Campylobacter jejuni, C. coli and the more uncommon C. lari are thermophiles, with 
an optimum growth temperature of 42 °C, making poultry and birds an ideal reservoir. 
Emerging Campylobacter species, however, have an optimal growth temperature of 
37 °C, making humans and other mammals ideal reservoir candidates. As such, 
Campylobacter species are ubiquitous, and sources of Campylobacter infections 
plentiful, as is the spectrum of possible clinical manifestations 21 (Figure 2).  
 
Whole-genome sequencing of C. jejuni has revealed extensive genetic variation 
between isolates. Hypervariable sequences in proteins involved in modification of the 
capsule, lipooligosaccharide (LOS) and flagellum as well as exchange of DNA 
between strains, allow the bacterium to continually evolve to adapt to the surrounding 
environment and evade host immune recognition.23  
C. jejuni has the ability to attach to human intestinal cells, subsequent to adherence 
through proteins on the bacterial surface that interact with the epithelial cells. This 
induces a proinflammatory response, characterized by IL-8 production that in turn 
recruits inflammatory cells such as neutrophils, dendritic cells and macrophages to 
enhance the inflammatory response resulting in diarrhea and bacterial clearance. It 
has been shown, that strains of C. jejuni have the ability to invade intestinal cells, but 
the role of this function in the pathogenesis of C. jejuni infection has not been 
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established. While cells of the innate immune system dominate the response to C. 
jejuni infection, human sera antibodies to bacterial components such as flagella and 
LOS have also been determined.23  
 
 
Figure 2: Sources of Campylobacter infection and the clinical manifestations. From 
Kaakoush et al. Clin. Microbiol. Rev. 2015;28:687-720. Reprinted with permission from 
ASM Press. 
 
Recognition of the importance of non-jejuni/non-coli Campylobacter species has 
increased, especially in the past two decades. These organisms are slow-growing and 
susceptibility to different antibiotics in selective medias limit their routinely detection 
in diagnostic laboratory settings. Reservoirs and disease associations of these 
emerging Campylobacters are still vaguely described, but the pathogenic potential of 
several of these species are becoming of increasing interest. This thesis focuses on C. 
concisus, whereas detailed descriptions of clinical and microbiological features of 
other emerging Campylobacter species can be found elsewhere.27  
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1.3. Campylobacter concisus  
Tanner et al. first described Campylobacter concisus in relation to humans in 1981, 
where it was isolated from the oral cavity of patients with periodontal lesions, and 
proposed to contribute to gingival destruction.28 It is a slow-growing, fastidious 
organism, with an optimal growth temperature of 37 °C, and a single polar flagellum. 
Biochemically, the species is urease and catalase negative, and oxidase positive.29 C. 
concisus is usually susceptible to ciprofloxacin and macrolides, but resistance to 
ciprofloxacin has been reported.30 While an animal reservoir has not been identified, 
it has been isolated from domestic pets,31, 32 fresh meat and poultry.33 Since the first 
isolation from the oral cavity, different studies have found that C. concisus was not 
only associated to disease but could be isolated and detected from healthy individuals 
as well.34-36 There has only been reported one case of extra-oro-intestinal infection 
with C. concisus, in a polymicrobial brain abscess from a male with intracranial 
carcinoma, 37 as well as one case of bacteremia with C. concisus following 
gastroenteritis, also in a male with a history of carcinoma.38 
 
1.3.1. Association to human gastrointestinal disease 
The first reports of a possible association to gastrointestinal disease were from 
children with diarrhea, initially reported from Sweden.39 A large study conducted at 
the Red Cross Children’s Hospital in South Africa over a period of almost two decades 
isolated Campylobacter species in 6.006 cases, and found that C. concisus accounted 
for 25.02% of these, thereby being the second most prevalent species after C. jejuni 
(32.57%).40, 41 Several studies conducted in Denmark have also found a high 
prevalence of C. concisus in diarrheic stool samples from both adults and children,42 
as well as immunocompromised individuals.43 Engberg et al. isolated C. concisus 
from the stools in a minority of healthy individuals, and a study from Belgium found 
that C. concisus was present in the stools of healthy children.44 In a large study on 
8.302 patients with diarrhea in Denmark, the incidence of C. concisus was found to 
be almost at high as for C. jejuni. From 11.314 faecal samples, 441 C. concisus isolates 
were recovered from 400 patients. C. jejuni/coli was isolated in 541 cases from 489 
patients. The study included 108 healthy volunteers, of which none had a C. concisus 
culture positive stool sample.30 Nielsen et al. described the clinical manifestations of 
enteric C. concisus infection, which include prolonged diarrhea with a milder course 
compared to C. jejuni/coli, also applicable for the pediatric population.45 Patients also 
had lower levels of serum inflammatory markers and a lower prevalence of fever, 
chills, mucus and blood in their stools, and interestingly, a possible association to 
development of microscopic colitis (MC) was noted.46 Recently, Underwood and 
colleagues used qPCR for C. concisus detection in faecal samples from patients with 
diarrhea, using cut-off values validated for C. jejuni to assess clinical relevance levels. 
The prevalence of clinically relevant levels of C. concisus in samples was 18%, 
compared to only 5% for C. jejuni/coli.47 However, these results were not correlated 
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to cultivation rates, which would be interesting in terms of establishing clinical cut-
off values.  
 
Barrett’s esophagus (BE) is a premalignant condition related to chronic 
gastroesophageal reflux disease (GERD). A study from 2007 found C. concisus in 
biopsies from four out of seven patients with this condition but in none of the seven 
controls,48 These findings were confirmed in a later study that sampled biopsies from 
patients with BE, GERD and esophageal adenocarcinoma (EAC), as well as healthy 
controls. In this study, C. concisus was the predominant species in BE and GERD, but 
not in healthy controls or EAC. Interestingly, the authors found a strong association 
between C. concisus colonization and epithelial IL-18 production, a pro-inflammatory 
cytokine also involved in the pathogenesis of gastric cancer.49  
The first indication for a possible association between C. concisus and IBD was 
reported when Campylobacter species in biopsy specimens from children with CD 
were analysed, revealing a significantly greater presence of C. concisus DNA 
compared to biopsies from healthy controls.50, 51 Similar results were later described 
by Man and colleagues, who observed that 65% of faecal samples from patients with 
CD were positive for C. concisus, compared to 33% of faecal samples from healthy 
controls.51 The same findings have followed for patients with UC. Mahendran and 
colleagues found that biopsies from both CD and UC patients analyzed by PCR had a 
higher prevalence of C. concisus compared to healthy controls (p<0.05).52 In that 
study, the authors also compared the prevalence in four anatomical sites and found 
that C. concisus preferentially colonized the proximal large intestine in IBD patients, 
although it was present in all parts examined.52 Mukhopadhya and colleagues in 
Scotland also detected C. concisus more often in biopsy specimens from adults with 
UC compared to controls (p=0.0019).53 In contrast, the same research group examined 
the microbiota of children with newly diagnosed CD and found that, although 
Campylobacter species in general were common in pediatric biopsies, there was no 
difference in detection of C. concisus when comparing IBD patients and controls.54 
Zhang et al. found that there was no difference in the prevalence of C. concisus in 
saliva samples from IBD patients and healthy controls, and that C. concisus DNA was 
prevalent in the majority of individuals tested (18/18 IBD patients and 57/59 HC).36 
These results indicate that the oral cavity is a possible reservoir for C. concisus, and 
that an association to IBD is only related to isolates present in the gut. 
 
 
1.3.2. Species diversity - Isolation and identification methodology  
The preferred media for isolation of Campylobacter jejuni/Campylobacter coli in 
clinical microbiology laboratories is the modified charcoal cefoperazone 
deoxycholate agar (mCCDA).55 This method is simple and reliable for detection of C. 
jejuni, but Campylobacter species that are susceptible to cefoperazone in this media 
cannot be detected. While there is no gold standard for isolation of emerging 
Campylobacter spp. such as C. concisus, the best-described methodology is isolation 
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by filtration onto non-selective media, by the so-called ‘Cape Town protocol’.56 Using 
polyagarose filters with a pore size of 0.4-0.8 µm the spiraling movements of 
Campylobacter spp. can be utilized to separate these from other enteric bacteria in 
faecal samples.57  
Most Campylobacter species metabolize amino acids or tricarboxylic acid cycle 
intermediates for growth in microaerobic conditions. Six species, C. concisus, C. 
curvus, C. gracilis, C. rectus, C. showae, and C. ureolyticus have been described to 
require hydrogen or formate as an electron donor in this process.27 Recently, Lee et 
al. examined the growth of C. concisus in different atmospheres and observed that 
oral and enteric C. concisus isolates grew in anaerobic conditions without the presence 
of H2, formate or fumarate, although the presence of H2 increased growth.58 Different 
methods for attaining microaerobic and anaerobic atmospheres for cultivation of 
Campylobacter species are available; most commonly the gas generating sachets or 
automated gas delivery systems. In previous studies, no significant difference in 
cultivation rates between the two systems has been observed, although it appears that 
colony size may increase when using the automated gas delivery system.59-61 
Traditional laboratory methods to identify Campylobacter species have included 
various phenotypic, biochemical and serological tests, but as the number of 
Campylobacter species is on the rise, traditional tests become less useful in 
differentiating isolates from one another.62 Since the isolation of C. concisus from 
different clinical samples from patients with enteric disease and healthy controls, 
different typing systems have been used to characterize the species by genetic 
profiling. Vandamme et al. proposed a genetic diversity of C. concisus already in 
1989, where DNA-DNA hybridization was used to compare C. concisus strains from 
diarrheic patients with oral reference strains, revealing only 42-50% matched values.63 
These findings were supported in a later study from Belgium, where C. concisus 
strains from 37 children with diarrhea showed that 94.6% of these had distinct 
randomly amplified polymorphic DNA (RAPD) profiles.44 In 2002, Matsheka et al. 
described a typing protocol using pulsed field gel electrophoresis (PFGE), where 51 
of 53 strains had distinct PFGE profiles,64 findings later supported by RAPD 
analysis.65 A Danish study from 2002 used a lectin typing system based on the 
bindings of lectins to LPS extracts of C. concisus, from stools samples from patients 
with a variety of clinical conditions, including HIV, malignancies and IBD. The 
system grouped 44 strains into 13 patterns that did not correlate with the different 
clinical diseases.66 In 2005, Engberg et al. found that SDS-PAGE protein profiling 
and PCR amplification of the 23S rRNA gene resulted in clustering of 39 C. concisus 
isolates into two genomospecies (GS), while RAPD profiling found 34 isolates to have 
distinct profiles.67 Several other research groups have also proposed a similar 
grouping of C. concisus isolates into two major genomospecies. Aabenhus et al. 
investigated 62 C. concisus isolates of mixed enteric and oral origin by AFLP profiling 
and found a clustering into four groups that were divided in two GS. Isolates from 
immunodeficient patients were included in this study, and interestingly, these isolates 
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were all assigned to AFLP cluster 4, from which the authors’ proposed that the GS 
may reflect variations in the pathogenic potential of isolates.68 Recently, Nielsen et al. 
conducted an MLST analysis of 63 faecal and four oral C. concisus isolates from 49 
patients with different clinical illnesses (29 with diarrhea, eight with bloody diarrhea, 
seven with MC, 5 with CD). Similar to previous findings, the isolates clustered into 
two major groups, but subgrouping was independent of clinical presentation.69 
Today, identification of Campylobacter species is more readily available by rapid 
molecular methods in a laboratory setting. Polymerase chain reaction (PCR) methods 
can amplify specific regions of DNA that are specific to different species. For C. 
concisus, the most widely used primers target the 16S rDNA, 23S rDNA or 
chaperonin-60 (cpn60) genes.31, 50, 70 Introduction of MALDI-TOF MS (Matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry) has enabled 
rapid typing of isolates, verified to be able to distinguish C. concisus from other 
Campylobacter species, and different C. concisus isolates from each other with unique 
spectras.71 With expansion of the C. concisus reference library, MALDI-TOF MS 
could be useful in strain differentiation in a routine laboratory.  
The most comprehensive method for genetic typing is whole genome sequencing, 
which will be discussed in detail later. Presently, nine C. concisus genomes have been 
sequenced and are available at GenBank in the National Center for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov/). These include three strains from CD 
patients (UNSWCD, UNSW2 and UNSW3), five from diarrheal faecal samples 
(13826/BAA-1457, UNSW1, UNSWCS, ATCC 51562), one from a faecal sample 
from a healthy individual (ATCC 51561) and one from the saliva of a patient with 
periodonitis (ATCC 33237). Only one isolate (13826 also known as BAA-1457) has 
been fully sequenced with complete closing of the genome. Kaakoush et al. were the 
first to compare the genomes of C. concisus, when they analysed the 13826 reference 
strain and the UNSWCD strain in 2011.72 They found that these two genomes only 
had 76% genes homology, and had significant differences in flagellin glycosylation 
pathways.72 Deshpande and colleagues subsequently conducted a comprehensive 
comparative study of eight of the above mentioned genomes and found that C. 
concisus strains could be grouped by pathogenic factors such as adherence, 
invasiveness and motility.73 Very recently, Chung et al. sequenced 27 oral C. concisus 
strains from IBD patients and HC and described two genomic islands (CON_PiiA and 
CON_piiB) that contained proteins homologous to a type IV secretion system, and 
effector proteins possibly involved in intracellular survival.74 The authors found that 
CON_PiiA islands were found in 3/8 enteric strains and none of the oral strains, and 
may therefore be associated to virulence (These genomes are at the time of writing 
not publically available).  
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1.3.3. Pathogenic potential 
As is the case for most pathogenic bacteria, virulence mechanisms can be classified 
by effect – invasion of host cells, evasion of host immune responses and induction of 
cell damage or dysfunction.75 Studies from the gastric microbiota have shown that C. 
concisus can tolerate wide variations in pH,76 and remains transcriptionally active in 
acidic environments.77 C. concisus has a single polar flagellum that allows for 
penetration through mucus, enabling contact with the gut epithelial cells, through 
flagellum-microvilli interaction.78 In-vitro studies have shown that C. concisus can 
invade host cells79 and that this potential is increased in the presence of the 
inflammatory cytokines TNF-α and IFN-ᵞ.78 Other in-vitro studies have shown that C. 
concisus isolates are capable of producing biofilm,80 and of inducing apoptotic leaks 
in epithelial cells.79 Interestingly, both of these properties were present in both faecal 
and oral isolates. In 2011, Kaakoush et al. found that strains isolated from chronic 
intestinal diseases were 500-fold more invasive than isolates from acute 
gastroenteritis cases and healthy controls. A plasmid containing various virulence 
determinants was detected in the chronic intestinal strains, which could explain the 
exceptional invasive potential of such isolates.72 The putative virulence factor from 
this plasmid is exotoxin9/DnaI that is associated to increased survival in epithelial 
cells. The same research group showed that exotoxin9/DnaI levels were significantly 
higher in faecal samples from CD patients compared to healthy controls.81 Kaakoush 
et al. also described in detail the secretome of C. concisus in which an abundance of 
secreted proteins known to be associated to virulence in other species, were 
identified.82 The same group also described upregulations of inflammatory pathways 
in the innate immune response by transcriptomic and proteomic analysis of infected 
macrophages.83 One of the key elements involved in barrier damage is believed to be 
Zot (Zonula occludens toxin), a toxin that targets intercellular tight junctions. The zot 
gene was initially described in Vibrio cholera, where it encodes a protein capable of 
disassembling tight junctions between epithelial cells leading to increased 
permeability, an important link to the clinical finding of secretory diarrhea.84 
Deshpande et al. investigated the epithelial response to Zot in Caco-2 cells using 
RNAseq and found that PAR2 expression, cytoskeletal remodeling and cytokine 
production was upregulated following Zot exposure.85 The changes in tight junctions 
after exposure to Zot are reversible and by investigation of zot sequences from 
different isolates, Mahendran et al. described that polymorphisms in the zot gene may 
be associated to clinical disease, rather than just the presence of zot by itself.86 
Recently, the same research group investigated several other Campylobacter species 
for the presence of zot, and identified twelve zot genes from nine species/subspecies 
that could be divided into two main groups, related to the diversity of the encoded 
proteins.87  
Based on some of the virulence properties mentioned above, Kaakoush et al. have 
proposed a division of pathogenic C. concisus isolates into two groups: adherent and 
invasive C. concisus (AICC), and adherent and toxinogenic C. concisus (AToCC), 
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similar to classification systems used for E. coli of which some subtypes have 
previously been associated to CD.29, 88 (figure 3).  
 
 
 
 
 
Figure 3: Pathogenic C. 
concisus strains can be 
divided into two types 
(AICC) and (AToCC) 
From: Kaakoush et al. 
Inflamm Bowel Dis 
2014;20:2189-2197 
Reprinted with 
permission from 
Wolters Kluwer Health, 
Inc. 
 
1.4. Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is comprised of two major diseases: Crohn’s 
disease (CD) and Ulcerative colitis (UC) (ICD-10: K50-K51) – both characterized by 
an excessive immune response to an unknown microbial trigger, in genetically 
susceptible hosts 89, 90 (Figure 4). Microscopic colitis (MC) is another chronic illness 
in the IBD group, but the etiology and clinical course of the disease distinguishes it 
from UC and CD, and it will not be discussed in more detail in this thesis. The etiology 
of UC and CD are believed to be same or closely related, although an exact pathogenic 
mechanism has yet to be described. Genetic studies have identified susceptible loci 
with an association to IBD, and a recent genotype association study proposed that 
disease location is in part genetically determined, while disease presentation and 
behavior are not.91 The incidence and prevalence of CD and UC are on the rise on 
every continent, and currently affects approximately one in 200 people in Europe and 
5 million people worldwide.92 The direct expenditures related to health-care are 
estimated to be €4.6-5.6 billion annually in Europe and indirect costs such as reduced 
work capacity are thought to exceed that number. Moreover, reduced quality of life, 
and social stigmata can influence the patients and their families for long periods of 
time.93 Historically, the incidence of IBD has risen steadily in Western industrialized 
countries since the recognition of the disease in the 1900’s. Furthermore, newly 
industrialized countries in Asia and the Middle East with dense populations continue 
to describe an increase in IBD incidence, indicating that the burden of disease is 
surging worldwide.94  
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Many studies have examined genes and genetic loci that could be implicated in the 
development of IBD and as of 2016, 163 susceptibility loci have been identified. Some 
loci are associated to either UC or CD exclusively, while others are shared in both 
diseases. The implicated genes are related to different aspects of intestinal 
homeostasis, such as barrier function, epithelial restitution and autophagy.89 One of 
the most widely studied genes is NOD2, which was the first to be associated to CD.  
NOD2 is a protein with a key function in immunoregulation, expressed in gut 
epithelial cells. Under normal circumstances, it detects peptidoglycans from microbes 
in the gut lumen, and activates the production of mucin and antimicrobial peptide 
through complex signaling processes. Loss-of-function mutations in the NOD2 gene 
are associated to the development of CD, by loss of protective inflammatory response 
and barrier function, which can lead to dysbiosis and chronic inflammation.95 Other 
genes that have been associated to IBD through an altered immune response to 
bacteria are IL23R and ATG16L1. With the expansion of genome-wide association 
(GWAS) studies, it has become apparent that genetic risk is associated to disease sub 
phenotypes 91 and that the interaction between genetic determinants and dysbiosis is 
a crucial element in IBD development.96 
Figure 4: A Venn-diagram depicting the overlapping etiologic factors in IBD. From Hold et 
al. World J Gastroenterol. 2014;20:1192–1210 Reprinted under the Creative Commons 
Atttributions Licence (CC- BY). 
 
The increase in IBD incidence in developing countries as these become industrialized 
underlines the fact, that environmental factors also play a part in IBD pathogenesis 
and over the years, different exposures have been examined. The first associative 
factor to be described was smoking – which increases the risk of developing CD while 
having a protective effect on the development, maintenance and severity of UC.97 
Other environmental factors that have been examined are use of NSAIDs, oral 
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contraceptives, psychiatric disorders and diet.98 The use of antibiotics during 
childhood has also been shown to be associated to the development of IBD,99 although 
a direct causal effect is difficult to establish as symptoms of IBD may have been 
present years prior to diagnosis leading to subsequent antibiotic treatment.  
Various specific enteric pathogenic bacteria have been proposed to be involved in the 
pathogenesis or exacerbation of IBD. Dating back as far as 1913, Dalziel, a Scottish 
surgeon, first described CD by comparing it to Johne’s disease in cattle which is 
caused by Mycobacterium avium subspecies paratuberculosis.100 Lack of 
epidemiological support and unresponsiveness to traditional antimycobaterial drugs 
have contradicted this association, but the theory is still disputed.101 Another 
bacterium of interest has been pathogenic E. coli strains, after descriptions of certain 
adherent strains being present in mucosal tissue of patients with CD, but not in healthy 
controls.88, 102, 103 Similarly, alpha-haemolysin producing E. coli have been shown to 
be capable of producing focal leaks in colonic epithelia.104 In a Danish population-
based cohort study the authors found an increased risk of IBD diagnosis following 
Campylobacter and Salmonella gastroenteritis (RR=5.4-9.8 in the first year after the 
positive faecal sample).105 However, there is also an increased risk of IBD diagnosis 
after having a negative stool test, indicating that patients who develop IBD have a 
history of increased stool sampling, probably parallel to disease evolvement.106 
Clostridium difficile, known to cause antibiotic-associated diarrhea and 
pseudomembranous colitis, has also been investigated in relation to IBD patients, as 
studies have shown that up to 10% of IBD patients will develop C. difficile infection 
at some point.107 However, there is little literature to support a causative association 
and the existence of C. difficile in IBD may merely be due to an inflammatory status, 
although positive findings in IBD should lead to eradicative treatment.108 In contrast, 
studies have proposed an inverse relationship between IBD and Helicobacter pylori, 
based on in-vitro studies have shown that H. pylori infected patients have lower 
systemic levels of the proinflammatory cytokines type 1 IFN-gamma and IL-12,109 
recently confirmed in a large meta-analysis.110 Likewise, other bacterial genera have 
been suggested to offer protective effects in IBD, for example Bacteroides, 
Bifidobacterium, Lactobacillus and Faecalibacterium, by several mechanisms 
including down-regulating production of inflammatory cytokines.11 Faecalibacterium 
prausnitzii ferments dietary fibers and produces butyrate, a short-chain fatty acid, 
which is a primary energy source for colonic epithelial cells. Several studies have 
shown that the prevalence of F. prausnitzii is depleted in both UC and CD patients, 
and it has been proposed that probiotic treatment with F. prausnitzii strains could be 
beneficial in IBD management.111-113  
Specific viruses have also been examined for possible associations to IBD, including 
Varicella zoster, Cytomegalovirus and Epstein-Barr virus. The implications of these 
virus in the pathogenesis of IBD is uncertain and comprehensive studies on this topic 
are lacking.114 An interesting study by Norman and colleagues focused on 
characterizing the human virome, the viral counterpart to the bacterial genome. They 
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found, that while IBD patients have decreased bacterial diversity in faecal samples, 
the viral diversity was increased – especially in the form of bacteriophages. 
Bacteriophages are responsible for the horizontal transfer of genetic material among 
bacterial communities, including those for pathogenesis, and the inverse relationship 
between bacterial and viral diversity in IBD may provide interesting information 
about the conformation of bacteria involved in the inflammatory process.115  
The microbiota of IBD patients has been reported to express less diversity than in 
healthy individuals, characterized by fewer Firmicutes and Bacteroidetes that 
generally express anti-inflammatory properties and more Proteobacteria with 
proinflammatory properties.116 Genome-wide associations studies (GWAS) indicate 
that IBD is biologically heterogeneous and metagenomics analysis indicate that this 
is also the case for the microbiota.117 Shifts in microbial composition may rely on 
severity of inflammation, disease states and genetic disposition, as well as 
environmental modulations such as anti-inflammatory or antibiotic drug use. On a 
cellular level, bacterial interaction with gut mucosa cells may rely on the mucosa 
composition, barrier defects, and the local host-mediated inflammatory response. 
Recognizing the diversity of IBD manifestations in different individuals is essential 
in attempting to improve treatment modalities and patient care, and individualized 
treatments are becoming of increasing interest.118 
While clinical symptoms overlap, pathological findings separate and characterize the 
two disorders distinctly (Table 1), discussed in detail below. 
 
Table 1: Differential diagnosis of UC and CD.  
Findings  UC CD 
Clinical  Perianal disease 
Fistulas 
Abscesses  
Strictures 
Rare Common  
Endoscopic Rectal involvement 
Pattern 
Always 
Continuous 
Unusual  
Skip lesions 
Imaging Ileal involvement Rare (Backwash) 75% 
Histological Inflammation depth 
Granulomas 
Fissures 
Crypt architecture 
Crypt abscesses 
Mucosa/submucosa 
No 
Rarely 
Distorted 
Yes 
Transmural  
20% 
Common  
Normal 
Yes  
Adapted from Baumgart, D. C. & Sandborn, W. J. Inflammatory bowel disease: clinical 
aspects and established and evolving therapies. Lancet 369, 1641-1657 (2007). 
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1.4.1. Crohn’s Disease  
Crohn’s disease is defined by inflammation of all layers in the intestinal wall and skip 
lesions that can affect the entire gastrointestinal tract, from the mouth to the anus. The 
most common symptoms at the time of diagnosis include diarrhea, abdominal pain, 
fever, and stools with blood or mucus or both. Complications associated with Crohn’s 
disease are related to the transmural lesions, with risks of perforations, fistulas and 
strictures. Diagnosis is based on a combination of clinical findings, endoscopic 
features such as cobble stoning, fissures, fistulas and ulcers, as well as histological 
features such as inflammatory cell infiltration, crypt irregularity or granulomas.119 
Imaging studies, such as CT or MRI can assist in determining the extent of disease 
and possible complications such as sclerosing cholangitis. The Montreal classification 
can be used to describe the extent of disease, and disease severity, encumbering age 
at diagnosis, extent of inflammation and disease behaviour.120 The disease is slightly 
more common in women (1.3-1.5:1), and age at disease onset is approximately 15-30 
years. It has been reported, that 13-20% of CD patients have a chronic active course 
of disease activity, 67-73% have a chronic intermittent course and 10-13% are in 
sustained remission.119  
1.4.2. Ulcerative colitis  
The inflammation in UC is limited to the mucosa and submucosal layers of the 
intestinal wall. The rectum is always affected, wherefrom inflammation spreads 
proximally in a continuous fashion. Apart from cases with backwash ileitis, the ileum 
is never involved, and the severity of symptoms and degree of colonic involvement is 
used to classify the disease.120 Complications are less common than in CD, and are 
abscesses and necrosis of colonic tissue, that can ultimately result in toxic megacolon 
with perforation. Ulcerative colitis affects men and women almost equally, and the 
age of onset has a bimodal peak between the ages of 15-30 and 50-70.121 The main 
symptoms at presentation are bloody diarrhea, pus or mucus in the stool, and 
abdominal cramping.122 Endoscopic findings include loss of vascular pattern, 
granularity, friability with spontaneous bleeding, erosions and ulcerations. 
Pathological findings from microscopic examinations of mucosal biopsies are 
distortion of crypt architecture, immune cell infiltration of the lamina propria, mucin 
depletion erosion or ulcerations.121 A combination of clinical, endoscopic and 
histological findings comprise the diagnosis of UC, though infectious and other non-
infectious causes of the symptoms must also primarily be investigated and ruled out. 
It has been reported that the distribution of disease activity is relatively constant, with 
50% in clinical remission at any given time, while 20-30% will require surgery at 
some point, and 24% will have undergone a colectomy 10 years after diagnosis.123 
Medical treatment regimens include systemic or rectal application of 5-aminosalicylic 
acid (mesalazine) and/or corticosteroids, according to individual response and clinical 
presentation. Treatment of severe UC can be attempted with more complex 
immunological drugs such as tactrolimus, ciclosporin or infliximab, that specifically 
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target proinflammatory cytokines. Individual treatment regimens depend on disease 
extent and severity, and detailed treatment algorithms are available.121 Emergency 
surgery is performed in case of severe complications such as toxic megacolon or 
perforation, and can also be performed electively in case of intolerance or non-
responsiveness to medical treatment.121  
 
1.4.2.1 Ileal-anal-pouch-anastomosis surgery and pouchitis  
Restorative proctocolectomy with ileal-anal-pouch-anastomosis (IPAA) has been the 
surgical treatment of choice for medically refractory UC since the introduction of the 
procedure in 1978.124 The procedure is usually carried out in two stages, initially with 
complete colectomy and ileostomy, later reversed to incorporate the distal ileum as a 
reservoir for stool, allowing for restored intestinal continuity.121 The most common 
complication to IPAA surgery is pouchitis – inflammation of the pouch. It his reported 
that 50% of patients that undergo IPAA will develop pouchitis at some point, most 
commonly within the first year post-surgery.125 An estimated 5-10% of patients will 
develop chronic pouchitis, which is the most common reason for pouch failure.126 The 
course of pouchitis comprises a wide spectrum of clinical presentations such as 
increased stool frequency, urgency, incontinence, abdominal pain, bloody stools and 
fatigue.127 Diagnosis should be based on a combined assessment of symptoms, 
endoscopic and histological findings,128, 129 although the disease is heterogeneous and 
a mismatch between clinical symptoms and endoscopic findings is not uncommon.130 
While treatment modalities should be individualized, they usually include antibiotics 
that can relieve symptoms.129, 131 The therapeutic effects of antibiotic treatment 
indicate that the gut microbiota is involved in the pathogenesis of pouchitis. After 
ileostomy closure, the ileal epithelium of the pouch becomes colonic in appearance in 
accordance with faecal stasis, and the bacterial communities begin to resemble those 
of the colon, more than those of the ileum.132 McLaughlin et al. analysed pouch 
biopsies from patients with IPAA due to UC (UC-IPAA) and familial adenomatous 
polyposis (FAP), both with and without pouchitis by 16S rRNA gene sequencing. 
They found a significant increase in Proteobacteria spp. in patients with UC but 
without pouchitis, compared to FAP patients with no pouchitis, and found that 
bacterial diversity was higher in UC patients without pouchitis compared to those with 
pouchitis.133 Microorganisms such as Clostridium difficile,134 Campylobacter135 and 
Cytomegalovirus136 have been suspected of being involved in the etiology of 
pouchitis, but a clear correlation to any specific microorganism has yet to be 
established. Activity of the adaptive immune system in patients with pouchitis mimics 
the finding in UC with increased proliferation of inflammatory cells and production 
of proinflammatory cytokines in the gut mucosa.127 In general, the development and 
maintenance of pouchitis resembles the natural course of UC, where an initial acute 
inflammatory response can become persistent, and patients with pouchitis represent 
UC patients with the most severe form of disease. 
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CHAPTER 2. OBJECTIVES 
While research to support the role of certain pathogenic strains of C. concisus in IBD 
is mounting, cultivation of isolates from the gut mucosa has been very limited. The 
presence of C. concisus DNA does not differentiate between viable and transient 
strains, and isolates for genetic comparison of intra- and interpersonal strain 
differences are needed in order to elucidate a possible association to enteric disease.  
The aims of this thesis were: 
1) To optimize cultivation procedures of C. concisus from gut mucosal biopsies 
from IBD patients and healthy controls, with the aim of determining the 
prevalence of viable C. concisus in the intestine.  
 
2) To evaluate genetic differences in intra- and interpersonal C. concisus 
isolates from stool, saliva and gut mucosal biopsies from IBD patients and 
healthy controls by using whole genome sequence data. 
 
3) To assess the clinical significance of C. concisus colonization in the 
gastrointestinal tract by investigating the existence of virulence associated 
genes in isolates from IBD patients and healthy controls. 
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CHAPTER 3. MATERIALS AND 
METHODS 
3.1. Study participants and inclusion 
Participants for this study were included during the period May 2014 – December 
2015, and were adults (>18 years), from North Jutland, Denmark. Participants were 
either patients with IBD or healthy controls (adults with a family history of colonic 
cancer or previously identified polyps, with no current symptoms of gastrointestinal 
disease or persistent diarrhea, and no histological signs of IBD). Patients with IBD 
were further subdivided by disease phenotype into CD, UC or UC-IPAA. Participants 
were sent written information about the project when called in for routine 
colonoscopies, or when a colonoscopy was assigned in relation to ambulant 
assessment. Participants were excluded if they had received antibiotics in the four 
weeks prior to inclusion, if they were pregnant or for some reason not able to provide 
consent. Other exclusion criteria were malignancy, severe immunodeficiency, 
hemophilia or anticoagulant treatment.  
Oral and written consent to participate was obtained prior to the colonoscopy. The 
study was approved by the Ethics Committee of Northern Jutland (N-20130070). An 
overview of the patients’ baseline characteristics is outlined in Table 2, and detailed 
clinical information of each participant is presented in Appendix A. The response rate 
to participate was 37% for IBD patients, and 22% for healthy controls. Two IBD 
responders were not eligible for participation due to recent antibiotic treatment, and 
one HC was not eligible due to treatment with anticoagulants. In total, 57 IBD patients 
(13 CD, 17 UC, 27 UC-IPAA), 28 healthy controls and two patients with persistent 
diarrhea that had normal colonoscopies were included.   
Saliva and stool samples were obtained prior to colonoscopy whenever possible, and 
mucosal biopsies were sampled from the following anatomical locations: the terminal 
ileum (TI), cecum (CE), ascending colon (ASC), transverse colon (TRA), descending 
colon (DES), sigmoideum (SIG) and rectum (REC), when possible. For some patients, 
strictures due to disease complications or previous surgery prevented biopsies to be 
collected from all locations.  From UC-IPAA patients, mucosal biopsies were 
collected from the ileum (just proximally from the afferent limb), the proximal (PP) 
and distal pouch (DP). Biopsies were retrieved with sterile forceps (Medwork, Braun 
Scandinavia, Denmark) that were discarded after each individual use. Mucosal 
biopsies were not obtained from five IBD patients (1 UC, 4 CD) due to logistic 
challenges. Saliva was not obtained from one patient with UC and faecal samples were 
not collected from one patient with UC, one with UC-IPAA, two with CD and one 
HC. 
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Table 2: Baseline characteristics of all study participants.   
 IBD   HC GE 
Disease CD UC UC-IPAA   
Number 13 17 27 28 2 
Sex, male (%) 5 (38) 8 (47) 14 (52) 13 (46) 0 (0) 
Age, mean (range) 41 (24-59) 52 (33-69) 44 (21-63) 51 (30-69) 38 (20-57) 
Biopsies, median 
(range)* 7 (6-7) 7 (4-7) 3 (3-3) 7 (7-7) 7 (7-7) 
*Excluding patients where mucosal biopsies were not provided. 
 
3.2. Cultivation of Campylobacter concisus 
3.2.1. Saliva samples 
Saliva samples were smeared directly onto 5% blood agar plates with 1% yeast extract 
(SSI Diagnostica, Denmark), using cotton tip swabs. Two 5 mg vancomycin tablets 
(Neo-sensitabsTM, Rosco Diagnostica A/S, Denmark) were then placed on the plate, 
which was incubated for two days in a microaerobic (80% N2, 10% CO2, 5% H2, 5% 
O2) atmosphere at 37°C. Microaerobic conditions were attained using the Anoxomat 
Mart II system (Mart Microbiology B.V., Netherlands) (Figure 5). Following 
incubation, growth from around the vancomycin tablets was harvested using 
inoculation loops, and liquefied in 100 µL sterile saline. Three to four drops from this 
emulsion was then transferred onto polycarbonate filters (0.6 µm pore size) 
(Whatman® Nuclepore™, Sigma-Aldrich, MO, USA) and incubated at 37 °C for one 
hour in an ambient atmosphere. Filters were subsequently removed with sterile 
forceps and the agar plate incubated in microaerobic atmosphere for a total of 96 
hours, according to the previously described protocol.57 Plates were inspected daily 
and colonies resembling Campylobacter species were investigated by wet mount 
microscopy and identified by mass spectromentry using the Matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF MS) (BRUKER DALTONIK 
GmbH, Bremen, Germany). Identification was also confirmed with qPCR analysis 
(Life Technologies, Carlsbad, CA, USA) using C. concisus specific primers137 
targeting the 16S rRNA gene with modifications of the methods of Mahendran et al.52 
 
3.2.2. Stool samples 
Study participants were instructed in collecting stool samples in dry containers that 
were sent by mail to the laboratory on the day of collection, rendering a transit time 
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of 2-4 days. On receipt in the laboratory, stool samples were kept refrigerated until 
diagnostic procedures were carried out, which was no later than 24 hours after 
reception. Two hundred milligrams of faeces was transferred to a clean eppendorf 
tube before processing, then labelled and stored in a biobank. The remainder of the 
stool samples were liquefied by addition of saline in volumes equivalent to the faecal 
mass, and vortexed until the emulsion was homogenous. Five to six drops of the 
emulsion was then transferred onto polycarbonate filters, incubated and processed as 
described for saliva samples.  
 
 
 
 
 
 
Figure 5: The Anoxomat Mart II 
chamber system. Used for 
implementing different incubation 
environments. (Author’s own photo). 
 
3.2.3. Mucosal biopsies 
Tissue samples were promptly placed in sterile containers with 0.5 ml sterile saline, 
marked with patient ID and location of sampling. Biopsies were then immediately 
taken to the laboratory, rendering a transit time of less than 30 minutes at ambient 
temperature. Each biopsy was smeared onto two 5% blood agar plates with added 
yeast extract using sterile inoculation loops.  
Cultivation was then carried out as a two-step procedure: Initially, one plate was 
incubated for 48 hours in microaerobic and the other in anaerobic (80% N2, 10% CO2, 
10% H2) conditions. Following 48 hours of incubation, inoculation loops were used 
to harvest approximately 100 µg bacterial mass by streaking across each agar plate. 
The bacterial mass was liquefied by addition of 50 µl sterile saline and brief vortexing. 
Using sterile pipettes, the emulsion was transferred onto two 5% blood agar plates 
with added yeast extract and polycarbonate filters, according to the previously 
described method for saliva and stool samples (Figure 6).  
Immediately after the biopsies were smeared onto agar plates for cultivation, they 
were placed in individual sterile tubes with sterile saline in preparation for DNA 
extraction. A detailed laboratory protocol for cultivation is presented in Appendix A.  
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Figure 6: Top left: Initial growth from a biopsy smear after two days incubation in micro-
aerobic atmosphere, transferred to plates with polycarbonate filters (top right). Bottom: 
Different phenotypic C. concisus cultures. Authors own photos. 
 
3.3. Polymerase Chain Reaction (PCR) 
3.3.1. Introduction to PCR 
In this study, qPCR was performed using the 7500 Real-Time PCR system (Applied 
Biosystems, Thermo Fischer Scientific, Massachusetts, USA). Standard curves used 
for quantification were generated by serial dilution of template DNA from a C. 
concisus isolate. A Ct-value of < 35 was considered positive, correlating to a bacterial 
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concentration of at least 1*102 CFU/ml. In all PCR runs, a negative template control 
(NTC) was included. PCR products were visualised on QiaExcel Advanced Screen 
Gel (Qiagen, Hilden, Germany) for verification of product size using an in-house 
protocol.  
3.3.2. PCR methods – Saliva and stool 
Extraction of DNA from saliva and stool samples was conducted in an identical 
manner. Approximately 100 µl of sample was mixed with 500 µl sterile saline and 
vortexed until homogeneous. Extraction was performed with the NucliSENS® 
easyMag® (BioMérieux, Marcy-l’Étoile, France) using the on-board protocol A with 
a final elution volume of 110 µl. The thermal cycling conditions for the C. concisus 
specific qPCR were 95°C for 10 minutes, followed by 40 cycles of 95°C for 30 
seconds, 60°C for 30 seconds and 72°C for 30 seconds on  The PCR reaction volume 
was 25 µl. The primers ConcFmod (5’-CAAGTCTCTTGTGAAATCCTATG-3’) and 
ConcR2 (5’-TTACTGCCAAGACTAGCTTAG-3’) targeting a 260 bp sequence of 
the C. concisus 16S rRNA gene were used in the reaction.137  
 
3.3.3. Mucosal biopsies 
Immediately following cultivation procedures, mucosal biopsies were placed in 2 ml 
safe-lock tubes with 500 µl sterile saline, 0.3 g glass beads (0.5 mm) and one stainless 
steel bead (5 mm). The tubes were beaten at 20 Hz for three minutes in a TissueLyser 
II (Qiagen, Hilden, Germany). Safelock tubes were then centrifuged for 30 seconds, 
after which the supernatant was transferred to clean eppendorf tubes. DNA extraction 
was performed as described above for saliva and faecal samples.  
DNA extracted from intestinal biopsies were subjected to a two step PCR. The 
bacterial 16S rRNA gene was first amplified from DNA extracted from intestinal 
biopsies using universal primers F27 (5’-AGAGTTTGATCCTGGCTCAG-3’) and 
R1496 (5’-TACGGCTACCTTGTT ACGAC- 3’), targeting a 1467 bp sequence from 
bacterial 16S rRNA.138 The thermal cycling conditions were 95°C for 10 minutes, 
followed by 35 cycles of 95°C for 20 seconds, 63°C for 20 seconds and 72°C for 1 
minute. The PCR reaction volume was 25 µl. The PCR product from this reaction was 
then purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany) 
according to the manufacturers instructions. The purified PCR product (5 µl) was 
subsequently subjected to a C. concisus-specific PCR using the primers ConcFmod 
and ConcR2, described previously. The detailed laboratory protocol and reagents used 
for all PCR reactions are presented in Appendix C. 
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3.4. Whole-genome sequencing (WGS)  
3.4.1. Introduction to WGS 
The first whole genome to be sequenced was the virus phage ɸX174, by Fred Sanger in 
1977.139 Sanger sequencing is a technology involving chain-termination, sometimes 
called the “dideoxy technique”. Dideoxyribonucleotides (ddNTPs) are chemical 
analogues of the deoxyribonucleoides (dNTPs) that lack the 3’ hydroxyl group, 
required for DNA extension. By adding a small volume of radiolabeled ddNTPs in a 
normal extension reaction, random incorporation into the copied DNA will result in 
different strand lengths. The reaction is performed in parallel for each individual 
ddNTP base (A, C, G, T), and the sequence is then determined by running the results 
on polyacrylamide gels.139 Sanger sequencing was modified to incorporate 
fluorometric based detection and capillary based electrophoresis, which led to the first 
commercialized sequencing machines.140 Whole genome sequencing is now routinely 
used in many clinical microbiology laboratories in identifying pathogens, resistance 
genes and for epidemiological surveillance of infectious diseases.141 
 
3.4.2. DNA extraction for WGS 
In our study, 104 C. concisus isolates were sequenced, representing isolates across the 
sampling frame to capture as much genetic diversity as possible (Appendix D). 
Isolates were cultivated as previously described and DNA extraction was performed 
using the QIAamp DNA mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturers instructions and quantified with the Qubit 2.0 Fluorometer (Invitrogen, 
Life Technologies, Carlsbad, CA, USA), and the Quant-iT DNA Assay Kit (Life 
Technologies, Paisley, UK), just prior to sequencing. The purity of DNA was assessed 
by measuring 260/280 OD on a Nanodrop 8000 (Thermo Fischer Scientific, 
Massachusetts, USA). The mean DNA concentration for the final products was 46.5 
ng/µl (range 20-60). The mean 260/280 OD was 2.0 (range 1.56-2.0).  
 
3.4.3. Sequencing method 
Whole genome sequencing was performed using a MiSeq desktop sequencer 
(Illumina, San Diego, California, U.S.A). The Illumina NGS workflow is based on 
four steps: Initial DNA extraction and library preparation with DNA fragmentation 
and ligation of adapters. This is followed by a PCR technique termed bridge 
amplification, and the resulting clusters are subsequently sequenced by incorporation 
of fluorescently labelled nucleotides that emit signals corresponding to the different 
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bases. Following sequencing, reads are aligned and assembled with computer based 
programs, prior to data analysis. 
(http://www.illumina.com/techniques/sequencing/dna-sequencing/whole-genome-
sequencing.html). 
Genome sequencing was performed on an Illumina MiSeq sequencer using the KAPA 
Low-Throughput Library Preparation Kit with Standard PCR Amplification Module 
(Kapa Biosystems, Wilmington, MA), following manufacturer’s instructions except 
for the following changes: Seven hundred and fifty nanograms  DNA was sheared at 
30 psi for 40 s and size selected to 700–770 bp following Illumina protocols. Standard 
desalted TruSeq LT and PCR Primers (Integrated DNA Technologies ,Coralville, IA) 
were used at 0.375 and 0.5 µM final concentrations, respectively. PCR was reduced 
to 3–5 cycles. Libraries were quantified using the KAPA Library Quantification Kit 
(Kapa), except with 10 µl volume and 90-s annealing/extension PCR, then pooled and 
normalized to 4 nM. Pooled libraries were re-quantified by ddPCR on a QX200 
system (Bio-Rad), using the Illumina TruSeq ddPCR Library Quantification Kit and 
following manufacturer’s protocols, except with an extended 2-min 
annealing/extension time. Libraries were sequenced using 2 × 250 bp paired end v2 
reagent kit on a MiSeq instrument (Illumina) at 13.5 pM, following manufacturer’s 
protocols. Reads were obtained from SeqWright (Houston, TX). Short read paired-
end data was assembled using the de novo assembly algorithm, Velvet (version 
1.2.08).142 The VelvetOptimiser script (version 2.2.4) was run for all odd k-mer values 
from 21 to 99. The minimum output contig size was set to 200 bp with the scaffolding 
option switched off; all other program settings were left unchanged. The average 
number of contigs was 92 (range: 3-356) for an average total assembled sequence size 
of 1.94 Mbp (range: 1.78-2.22). The average N50 was 97693 (range: 13858-934037) 
and the average GC content was 38.94% (range: 37.26-39.88). Contigs were 
individually archived in sequence bins on the web-based platform BIGSdb.143  
Assembled genome data and individual genome coverage information is presented in 
Appendix E, along with corresponding BIGSdb ID’s. Genomes are pending 
submission to the NCBI database.  
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3.4.4. Data analysis – the Bacterial Isolate Genome Sequence Database 
(BIGSdb) 
The Bacterial Isolate Genome Sequence Database (BIGSdb) is a web-accessible 
database that holds sequence information for thousands of bacterial isolates.143  The 
sequence information is linked to isolate records and metadata, and can be used for 
genome comparison and BLAST searches for specific gene content (Figure 7). Data 
is exported as tab-delimited text files or concatenated sequences in FASTA format for 
use in various analyses.   
 
Figure 7: The BIGSdb worklow. From: Jolley & Maiden, BMC Bioinformatics 2010, 11:595. 
Reprinted under the Creative Commons attribution licence (CC-BY). 
 
Orthologous genes were defined as homologous genes that had ≥ 70% nucleoide 
identitiy and < 50% difference in alignment length (default settings).   
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3.5. Multi-Locus sequence typing (MLST) 
Multi-locus sequence typing was introduced as a method for typing of bacterial 
microorganisms in a way that information could be exchanged between laboratories 
and used for epidemiological purposes.144 In MLST schemes, a number of 
housekeeping genes (usually at least seven) are sequenced and each assigned an allele 
number. The combined allelic profile is then assigned a sequence type (ST). The 
assignment of a unique allele disregards how many nucleotide polymorphisms are 
involved. MLST allele sequences and ST profile tables for bacterial species are stored 
in online databases, and can be collectively accessed from www.pubmlst.org, hosted 
by the Department of Zoology at the University of Oxford.  
We used the MLST scheme defined by Miller et al., which targets the seven loci: 
aspatase (aspA), ATP synthase subunit alpha (atpA), glutamine synthetase (glnA), 
citrate synthase (gltA), serine hydroxyl methyl transferase (glyA), dihydroxy-acid 
dehydratase (ilvD) and phosphor glucomutase (pgm).145 For comparison, we also used 
the scheme described by Ismail et al., using the six housekeeping genes validated for 
MLST of C. jejuni that also include aspA, glnA and atpA, as well as glucose-6-
isomerase (pgi), transketolase (tkt) and aspartate-semialdehyde dehydrogenase 
(asd).146 
Sequences of housekeeping genes of C. concisus isolates were aligned and compared 
in BIGSdb, and phylogenetic trees were generated using the MEGA7 tool by applying 
the neighbor-joining method with 500 bootstrap replications.147 Campylobacter 
curvus 525.92 (Accession No. CP000767.1) was used as an outgroup. For each 
housekeeping loci, the different sequences were assigned distinct allele numbers. The 
combination of allelic profiles is pending ST assignment and isolates with identical 
STs were defined as the same strain.  
 
3.6. Zot and Exotoxin 9 BLAST searches 
The DNA sequence for the zot and exotoxin 9/ DnaI gene were was obtained from the 
NCBI database (https://www.ncbi.nlm.nih.gov/tools/primer-blast/), and aligned by 
BLAST in BIGSdb as described above. Nucleotide sequences, polymorphisms and 
amino acid alignments were visualized using the online BioEdit software 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html.) 
 
Primers used for these analyses are listed in table 3.  
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Table 3: List of primers used for zot and exotoxin 9 detection 
Target Name Sequence (5’→3’) Size* 
(bp)  
Ref. 
 
Zot FCCC13826_2075 TGCAAACCCTTTGTGATGAA 1055 86 
 Ccon_zotR_257 TCGGTCCTCCACGATCTG  148 
 Zot1 GCAACTTAGAAAAAGTATCGG 790 72 
 Zot2 TAATAGTTCTCGATGAAGCC  72 
 ZotF CTAGAATCAGTTTGTGGAGAT  72 
Exotoxin 9 Exotox-F GAGACAAAGCTGCTTTAT 291 149 
 Exotox-R CTATCAAGATTAAAGCCG   
* Size of target sequence. 
  
3.7. Statistical analysis 
Data was analysed using Stata 14 (Statacorp LP, Texas, USA). Where applicable, the 
chi2 test was used for dichotomous variables and McNemar’s test for paired nominal 
data. A p-value < 0.05 was considered statistically significant. When comparing 
groups in study II and III, comparison was calculated between the number of patients 
rather than the number of isolates, i.e. a patient was several positive isolates from the 
same location counted as only one, since the number of isolates from each individual 
varied. 
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CHAPTER 4. RESULTS 
4.1. Study I  
Patients that did not provide gut mucosal biopsies were not included in the first study, 
and neither were patients with diarrhea. One of the healthy controls in the total 
population was not included until after study I was complete, resulting in 78 subjects 
in total, included in study I. (CD=9, UC=16, UC-IPAA=27, HC=26). 
 
4.1.1. Cultivation from Gut Mucosal Biopsies 
In total, 427 biopsies were collected from the 78 subjects. The number of biopsies 
collected at each anatomical site from the different disease categories is presented in 
Table 4.  
Table 4: Number of biopsies attained at each location for the different patient groups.  
 IBD HC 
Subgroup CD UC UC-IPAA  
Number of participants 9 16 27 26 
Terminal ileum 8 9 - 26 
Cecum 9 14 - 26 
Ascending colon 9 15 - 26 
Transverse colon 9 16 - 26 
Descending colon 9 16 - 26 
Sigmoideum 9 16 - 26 
Rectum 9 16 - 26 
Ileum (UC-IPAA) - - 27  
Proximal pouch (UC-IPAA) - - 27  
Distal pouch (UC-IPAA) - - 27  
Total 62 102 81 182 
 
Isolates that grew in both microaerobic and anaerobic atmospheres were collected 
separately, rendering a total of 99 isolates. Twenty-nine isolates were derived from 
microaerobic and 22 from anaerobic incubation exclusively (p=0.40). From 24 
biopsies, isolates grew in both atmospheres (Table 5).  
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Table 5: Number of isolates collected from microaerobic and anaerobic cultivation 
Incubation method IBD (%) HC (%) 
Microaerobic only 18 (25) 11 (39) 
Anaerobic only 17 (24) 5 (18) 
Both  36 (51) 12 (43) 
Total  71 28 
 
In all IBD patients, a total of 52/245 (21%) biopsies were culture positive for C. 
concisus, while 121/245 (49%) were PCR positive (p<0.001). For healthy controls, 
the numbers were 23/182 (13%) and 66/182 (36%), respectively (p<0.001). The rate 
of cultivation and PCR detection was higher for IBD patients compared to healthy 
controls (p=0.021 and p=0.008, respectively), but interestingly, it was significantly 
higher for UC-IPAA patients compared to other IBD patients (p=0.0001 and 
p=0.0006, respectively) (Figure 8). 
 
Figure 8: Percentage of positive biopsies (in total) by cultivation and PCR from the different 
patient groups. 
 
Agar plates were also inspected for Campylobacter species other than C. concisus. 
The majority of these were C. ureolyticus, with six isolates recovered from six 
different IBD patients. One of these patients was also positive for C. concisus. One 
IBD patient had C. curvus in three different biopsies; another had one C. showae 
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isolate in one biopsy. Both of these patients were also positive for C. concisus. In the 
healthy control group, isolates of C. ureolyticus and C. showae were recovered from 
four different individuals, whereof two were also positive for C. concisus. No 
thermophilic Campylobacter species were isolated from IBD patients or healthy 
controls. 
4.1.2. Cultivation of saliva and stool samples 
From stool samples, 12/48 (25%) isolates from IBD patients were culture positive, 
while 19/48 (40%) were positive by PCR detection. For healthy controls, the numbers 
were 3/25 (12%) and 5/25 (20%) respectively. There was no difference between 
groups by cultivation (p=0.18), but a significantly higher amount of positive stool 
samples by PCR in the UC-IPAA subgroup (p=0.001). As expected, C. concisus was 
abundant in saliva samples from both IBD patients and healthy controls, with 34/51 
(67%) IBD and 18/26 (70%) healthy controls being culture positive, while 47/51 
(92%) and 23/26 (88%) were PCR positive, respectively.  
When assessing the number of subjects with at least one positive C. concisus biopsy, 
stool or saliva sample, there was no difference between groups by cultivation (biopsies 
p=0.26, faeces p=0.12, saliva p=0.60) (Figure 9).  
 
Figure 9: Percentage of individuals with at least one culture positve C. concisus sample from 
biopsies, faecal samples and saliva. 
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When assessing PCR results, there was no difference in the number of people with at 
least one positive biopsy (p=0.06) or saliva sample (p=0.60), but just marginally, there 
were more UC-IPAA patients with a positive faecal sample (p=0.05) compared to the 
other groups. (Figure 10). 
Figure 10: Percentage of individuals with at least one PCR positve C. concisus sample from 
biopsies, faecal samples and saliva. 
 
When assessing clinical symptoms of the IBD patients in the study, there was 
significantly more UC-IPAA patients with clinical symptoms compared to CD 
patients and other UC patients (p=0.03). Clinical symptoms were diarrhea, blood or 
mucus in stool, abdominal pain, or fatigue, and were marked as present if the 
symptoms were worse than the patient’s usual status at baseline. Interestingly, the 
presence of endoscopic (ulcerations, edema, friability) and histological (polymorph 
infiltration, ulcerations) inflammation was not significantly different between groups 
(Table 6). 
Table 6: Number of IBD patients with clinical symptoms, endoscopic and microscopic signs 
of inflammation.  
 CD UC UC-IPAA p-value 
Clinical symptoms  
(%) 5/9 (56) 7/16 (44) 22/27 (82) 0.03 
Endoscopic 
inflammation (%) 4/9 (44) 7/16 (44) 18/27 (67) 0.26 
Microscopic 
inflammation (%) 5/9 (56) 7/16 (44) 21/27 (78) 0.07 
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4.2. Study II: MLST 
Multi locus sequence typing using the combination of loci defined by Miller et al. 
revealed a high diversity of C. concisus with 71 ST’s and the following number of 
alleles: aspA:63, atpA:65, glnA:62, gltA:64, glyA:62, ilvD:64 and pgm:63. The total 
length of the combined sequences was 3345 bp. For one isolate, the ilvD loci was 
located at the end of a contig and the allele therefore incomplete. The atpA loci was 
not present in the C. curvus 525.92 genome. C. concisus isolates clustered into two 
main groups corresponding to 23S rRNA genomospecies (GS I and GS II), with the 
majority of isolates in GS II (n=79). There was no association to disease status, as 
IBD patients, diarrheic patients and healthy controls were represented in both clusters 
(p=1.00). However, when assessing anatomical site of collection, there was 
significantly more mucosal isolates in GS II and oral isolates in GS I. (p<0.0001). 
Faecal isolates were equally present in both clusters (Figure 11).  
Figure 11: Neighbour-joining tree from concatenated MLST sequences of C. concisus 
isolates, displayed in radiation for visual interpretation of clustering into two groups. The 
colours represent disease state: Red = IBD, yellow = GE, green = HC. Shapes indicate site of 
sampling: circles = mucosal biopsies, diamonds = faecal isolates, triangles = saliva.  
I 
II 
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As previously mentioned, Deshpande and colleagues found that typing by 16S rRNA 
sequences showed a division of isolates that correlated to clinical presentation in the 
eight genomes sequenced in that study.73 In the isolates from our study, we found no 
correlation to disease presentation or sampling site when comparing 16S rRNA 
sequences. (Figure 12, left). We also assessed the MLST scheme presented by Ismail 
and colleagues, and found that clustering was identical to the findings when using the 
scheme of Miller et al., with 71 unique strains (Figure 12, right). The results discussed 
in the following are from MLST using the Miller scheme (aspA, atpA, glnA, gltA, 
glyA, ilvD and pgm), as this is the accepted scheme for entry into the Pubmlst database.  
 
 
 
Figure 12. Left: Neighour-joining dendrogram based on 16S rRNA sequences. Presented in 
radiation forms for visualization purposes. Right: Neighbour-joining dendrogram based on 
sequences from the six housekeeping loci described by Ismail et al 146. Colours and shapes 
represent disease states and sample location as described in figure 11.  
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Two or more isolates were collected from 27 patients (18 IBD, 2 GE, 7 HC). Isolates 
from 17 of these 27 patients (63%) were genetically different, with isolates from seven 
individuals (4 IBD, 1 GE, 2 HC) being represented in both GS. These findings were 
independent of clinical presentation and sampling site (Figure 13).  
 
 
Figure 13: Circular dendrogram of concatenated MLST sequences of C. concisus isolates, 
displaying individual variation. The colours represent different individuals, the shapes 
indicate sampling location as in figure 11 (see text for details). 
  
Two individuals had multiple isolates that were the same ST (Patient 35UC and 
10HC) (figure 14a). However, other patients with multiple isolates had more than one 
ST. Patient 12CD had several mucosal isolates and an oral isolate in the same ST in 
GS I, but two mucosal isolates with different STs in GS II. One isolate from GS I and 
an isolate from GS II were retrieved from the same biopsy (from the transverse colon) 
(Figure 14b). Interestingly three faecal and one oral isolate from patient (16UC (UC-
IPAA)), one oral isolate from a healthy control (8HC) and one mucosal isolate from 
a healthy control (9HC) were all the same ST. However, the mucosal isolates from 
patient 16UC belonged to GS II (figure 14C). 
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For some patients, isolates were collected at different time points: The faecal samples 
from the previously mentioned patient with UC-IPAA (16UC) were collected one 
month apart, but were all the same ST. Interestingly; one patient (1D) with diarrhea 
had three different isolates, represented in both GS. The faecal isolate was collected 
in 2012, and the two biopsy samples in 2015. This patient presented with intermittent 
episodes of prolonged diarrhea, but had no endoscopic or microscopic signs of 
mucosal inflammation. Another patient with diarrhea (25D) had two different faecal 
isolates in the same GS. These samples were collected two months apart and the 
patient was treated with ciprofloxacin in between sample collection (Figure 14d).  
 
 
Figure 14: Circular dendrograms displaying the distribution of a subset of different patients 
with several isolates. Top left (a): Patients 35UC (brown) and 10HC (green). Both patients 
only have isolates belonging to the same ST. Top right (b): Patient 12 CD. Bottom left (c): 
Patients 16 UC (bright green), 8HC (brown), 9HC (blue). Bottom right (d): Diarrheic patients 
1D (pink) and 25D (red). 
A B 
C 
D 
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4.3. Study III: Putative virulence factors Zot and Exotoxin 9 
BLAST searches for the zot gene and exotoxin 9 (used as a proxy for the UNSWCD 
plasmid) revealed that 67/104 (64.4%) isolates were positive for either zot or exotoxin 
9 DNA, or both. Eight isolates were positive for zot only, 50 for exotoxin 9 only, and 
nine had both zot and exotoxin 9 (Table 7). 
Table 7: Isolates positive for zot and/or exotoxin 9 and corresponding patient information 
Individual Disease 
Phenotype 
No. of 
isolates 
C. concisus isolates 
 
4UC UC 2 AAUH-4UCti (B), AAUH-4UCti_a (B) 
7UC UC-IPAA 1 AAUH-7UCil (B) 
8UC UC-IPAA 1 AAUH-8UCo (O) 
11UC UC 1 AAUH-11UCsig_a (B) 
12CD CD 1 AAUH-12CDrec_a (B) 
15UC UC-IPAA 1 AAUH-15UCdp (B) 
16UC UC-IPAA 6 AAUH-16UCf (F), AAUH-16UCf2 (F), AAUH-16UCf3 (F), 
AAUH-16UCo_a (O), AAUH-16UCdp3 (B), AAUH-16UC-
dp5 (B) 
20UC UC-IPAA 1 AAUH-20UCf (F) 
35UC UC-IPAA 7 AAUH-35UCdp (B), AAUH-35UCil_a (B), AAUH-
35UCil2_a (B), AAUH-35UCil3_a(B), AAUH-35UCil4_a 
(B), AAUH-35UCpp (B), AAUH-35UCf (F) 
37UC UC-IPAA 2 AAUH-37UCo (O), AAUH-37UCf (F) 
39CD  CD 3 AAUH-39CDf (F), AAUH-39CDti_a (B), AAUH-39CDrec_a 
(B) 
40UC UC 1 AAUH-40UCf (F) 
43UC UC 1 AAUH-43UCce-a (B) 
44UC UC 2 AAUH-44UCsig_a (B), AAUH-44UCsig6 (B) 
47UC UC-IPAA 2 AAUH-47UCil (B), AAUH-47UCil_a (B) 
48UC UC-IPAA 1 AAUH-48UCdp_a (B) 
49UC UC-IPAA 3 AAUH-49UCil_a (B), AAUH-49UCpp_a (B), AAUH-49UCf 
(F) 
51UC UC-IPAA 1 AAUH-51UCf (F) 
59UC UC-IPAA 1 AAUH-59UCpp_a (B) 
2HC HC 1 AAUH-2HCtra (B) 
3HC HC 2 AAUH-3HCo (O), AAUH-3HCco (B) 
6HC  HC 1 AAUH-6HC0_a (O) 
8HC HC 1 AAUH-8HCo (O) 
9HC HC 2 AAUH-9HCasc (B), AAUH-9HCco (B) 
10HC HC 9 AAUH-10HCco (B), AAUH-10HCtra (B), AAUH-10HCdes 
(B), AAUH-10HCdes2 (B), AAUH-10HCdes3 (B), AAUH-
10HCdes4 (B), AAUH-10HCdes5 (B), AAUH-10HCdes6 
(B), AAUH-10HCdes7 (B) 
11HC HC 2 AAUH-11HCo (O), AAUH-11HCf (F) 
12HC HC 1 AAUH-12HCf (F) 
14HC HC 1 AAUH-14HCco (B) 
15HC HC 1 AAUH-15HCti (B) 
20HC  HC 1 AAUH-20HCrec_a (B), AAUH-20HCsig_a (B) 
1D GE 3 AAUH-1Dasc (B), AAUH-1Dtra (B), AAUH-1Dce_a (B) 
5676 GE 1 AAUH-2010376221 
25D GE 2 AAUH-25Df (F), AAUH-25Df3 (F) 
Isolate origin: O: oral, B: biopsy, F: faeces. Blue=zot positive, green=exotoxin 9 positive, 
red=zot and exotoxin 9 positive. Reference strains are not presented in this table.  
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Several individuals had more than one C. concisus isolate, sometimes from different 
locations. In total, 17 out of 104 (16%) isolates were positive for zot, from 12 different 
patients (IBD n=8, HC n=3, GE n=1). The zot gene has previously been described in 
the reference isolate C. concisus 13826 (ATCC BAA-1457) and was in this study also 
detected in ATCC 33237. These sequences were included in the phylogenetic 
analysis, which showed grouping into two main clusters. No individual had more than 
one type of zot, regardless of sampling site (Figure 15). Three isolates were not 
included in the phylogenetic analysis because the genes were located at the end of a 
contig and therefore incomplete (AAUH-2010376221 (faecal isolate, diarrheic 
patient), 14HC (mucosal isolate, healthy control) and 11HC (faecal isolate, healthy 
control). 
 
Figure 15: A Phylogenetic tree based on the concatenated sequences of the zot gene in 14 
clinical C. concisus isolates and 2 reference isolates (13826 and ATCC 33237). Isolates 
deriving from IBD patients are marked with red, isolates from healthy controls in green. The 
shapes indicate sampling site: Circles = mucosal biopsies, diamonds = feacal samples and 
triangles = saliva. The numbers to the left of isolate names are the corresponding BIGSdb 
id’s.  
 
When analyzing nucleotide sequence data and amino acid composition, we found that 
none of our isolates had the zot350-351AC polymorphism previously described by 
Mahendran et al.86 The zotmultiple polymorphism was detected in three isolates (13826, 
44Ucsig6 and 44Ucsig-a). We found the zot808T mutation only in one mucosal isolate, 
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interestingly, from a healthy control (14HC). The amino acid substitutions from the 
polymorphism sites were equivalent to those previously reported by Mahendran et al., 
with a substitution of valine at position 270.86 We did not find any other unique 
polymorphisms or amino acid substitutions in our zot sequences that correlated to 
clinical presentation. 
 
In total, 59 (56.7%) isolates from 26 different patients (IBD n=15, HC n=9, GE n=2), 
had exotoxin 9 DNA. There was noticeably fewer isolates with exotoxin 9 only from 
IBD patients (37.1%) compared to HC (70.4%) and GE patients (71.4%). Nine 
isolates were positive for both zot and exotoxin 9 DNA, and all these nine isolates 
were from IBD patients, with the majority (n=6) originating from mucosal isolates.  
An overview of the number of zot, exotoxin 9 and combined positive isolates by 
disease phenotype is presented in table 8, and the number of positive isolates grouped 
by sampling site, in table 9. 
 
 
Table 8: The number of isolates positive for zot, exotoxin 9 and both, for each patient group. 
Factor IBD (n=70) HC (n=27) GE (n=7) 
zot only 3 (4.3%) 4 (14.8%)  1 (14.3%) 
Exotoxin 9 only 26 (37.1%) 19 (70.4%) 5 (71.4%) 
zot + Exotoxin 9 9 (12.8%) 0 (0%) 0 (0%) 
 
Table 9: The number of isolates positive for zot, exotoxin 9 and both, by sample location. 
Factor Saliva (n=14)  Biopsy (n=70) Stool (n=20) 
zot only 2 (14.3%) 3 (4.3%) 3 (15%) 
Exotoxin 9 only 4 (28.6%) 36 (51.4%) 10 (50%) 
zot + Exotoxin 9 1 (7.1%) 6 (8.6%) 2 (10%) 
 
 
Interestingly, when assessing the number of virulence genes in each GS, we found 
that the number of patients with isolates positive for zot only, were more prevalent in 
GS I (6/18) compared to GS II (2/39) (p=0.039), whereas the number of patients with 
isolates positive for exotoxin 9 only, was higher in GS II (20/39) compared to GS I 
(4/18) (p=0.004). The number of individuals with isolates positive for both virulence 
genes was not significantly different between the two GS (GS I: n=1, GS II: n=4) 
(p=0.56). 
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When assessing our dataset, it was apparent that simultaneous colonization with 
isolates both with and without virulence determinants was possible. One patient with 
Crohn’s disease (12CD) had 12 isolates in total. The majority of these, belonging to 
GS I had neither zot nor exotoxin 9, but one of the isolates, from GS II, was positive 
for zot. This isolate was recovered from a mucosal biopsy of the rectum, which did 
not differ from the other mucosal isolates in terms of macroscopic or histological signs 
of inflammation at the time of sampling. Seven isolates recovered from a patient with 
UC-IPAA (35UC) all had exotoxin 9 DNA, and interestingly, four also had zot. Some 
of these isolates were from the same biopsy. From one HC (8HC) two oral isolates 
were recovered of which one was positive for exotoxin 9 DNA while the other was 
not. One patient with UC-IPAA (37UC), and one HC (3HC) had an oral isolate with 
zot and a faecal isolate with exotoxin 9, belonging to two different GS. An overview 
of isolates in each GS with concordant virulence determinants is depicted in figure 
16. 
Figure 16: Circular dendrogram based on the concatenated sequences of seven housekeeping 
genes of C. concisus isolates with detected virulence genes. Isolates marked with blue are 
positive for zot, green for exotoxin 9 and red for both. Roman numerals indicate GS, that are 
separated by the black line. 
I 
II 
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CHAPTER 5. DISCUSSION 
5.1. Methodological considerations  
5.1.1. Cultivation 
Cultivation from saliva samples using the filter method is relatively simple, and yields 
a high rate of C. concisus from microaerobic cultivation with hydrogen. The rate of 
C. concisus positive faecal samples by cultivation is much lower. In this study, 
patients were asked to collect faecal samples prior to the colonoscopy procedure. The 
majority of faecal samples were sent to the laboratory by mail, and were therefore 2-
4 days in transit. A limitation to this sampling method is that the samples can be 
exposed to very high or low temperatures according to variable seasonal weather 
conditions, which could have an effect on the viability of C. concisus isolates. It is 
also possible that metabolites and waste products from other microorganisms in faecal 
samples could contribute to degradation of viable bacteria or bacterial DNA. 
Kaakoush et al. found a higher number of PCR positive faecal samples in a study 
examining diarrheic isolates of C. concisus from children with CD and HC (25/30 
(83.3%) and 23/30 (76.7%), respectively).150 These faecal samples were snap-frozen 
immediately until use in the study, possibly leading to better DNA conservation.  
Cultivation of C. concisus from mucosal biopsies has previously been only sparsely 
described. In some of the first studies to propose an association to IBD, biopsies were 
cultured on agarplates with added trimetoprim and vancomycin, then transferred onto 
polycarborbonate filters and incubated for 48 hours.50, 52 Kaakoush and colleagues 
used an enrichment-filtration procedure in which tissue samples were placed in Ham's 
F-12 enrichment broth prior to filtration onto agar plates. Using this method, they 
managed to collect three isolates from three out of 11 children with CD.149 The main 
differences in our study design, is that we used several biopsies from different 
intestinal locations, and combined cultivation in microaerobic and anaerobic 
atmospheres. While this “Aalborg two-step” method yields a high cultivation rate and 
facilitates growth, it is space consuming and tedious and therefore not suitable for 
application in a clinical context. We did not use enrichment broths for tissue samples, 
but this could be an interesting approach to enhancing C. concisus growth possibly 
reducing the need for multiple sample collection and allowing more time from sample 
collection to lab processing. We also used non-selective agar plates without added 
antibiotics. The rationale for using trimetoprim and vancomycin in agarplates is that 
they limit growth of gram-positive organisms and other gram-negative bacteria such 
as E. coli and Proteus species that may make it more difficult for C. concisus to grow. 
However, in our study, we did not encounter cultivation difficulties such as swarming 
or excessive growth from other organisms, indicating that non-selective medias are 
sufficient for C. concisus cultivation.  
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There are some basic environmental conditions that were not tested in our study, 
which could be useful in aiding the optimal cultivation procedures for C. concisus. 
Some outstanding questions that should be addressed are for example, in which 
temperature range C. concisus can grow. While C. jejuni has optimal growth 
conditions in the temperature range 30-46 °C, it maintains vital cellular functions such 
as ATP generation and protein synthesis at temperatures down to 4°C.151 Such 
investigations for C. concisus would also be valuable in assessing the possibility that 
C. concisus has an environmental reservoir. Another question is whether or not 
different enrichment broths could aid in initial growth of C. concisus and possibly 
enhance cultivation rates from clinical samples. As previously mentioned, Kaakoush 
et al. used the Ham’s F12 nutrient broth in cultivation of C. concisus from mucosal 
biopsies,149 and have previously also described growth in Brain Heart Infusion (BHI)80 
and Bolton broth, with increased growth rates in medias supplemented with horse 
blood.76 In a clinical context, investigations into the survival of C. concisus in routine 
transport medias such as the modified Cary-Blair media used in FaecalSwabsTM 
(Copan Diagnostics, Murrieta, CA, USA) remain to be investigated.  
While the studies in this thesis have focused on C. concisus in enteric disease, other 
non-jejuni/non-coli Campylobacters have also been proposed as potential pathogens 
of the gastrointestinal tract, especially C. ureolyticus and C. showae.51, 53, 54 We 
managed to culture C. ureolyticus, C. curvus and C. showae from different sample 
types, but at much lower rates than C. concisus. Although we did not perform PCR 
for other Campylobacter species, our results indicate that C. concisus is more 
abundant in the lower gastrointestinal tract than other emerging Campylobacter 
species that have the same nutritional growth requirements.  
 
5.1.2. Whole-genome sequencing 
Genomic analysis of bacterial isolates by WGS is becoming increasingly available in 
the clinical setting and will likely replace current technologies for bacterial typing in 
the near future. Currently, there is no “golden standard” for conducting or reporting 
on bacterial WGS, and there are several limitations to the analysis that must be 
considered. Throughout the WGS process from DNA extraction to data analysis, the 
quality of the in/output must be assessed and reported since analysis depends on the 
quality of the sequence.152 In a clinical context, user-friendly bioinformatics pipelines 
are becoming increasingly available, and this may streamline and uniform the WGS 
process and create more transparent results.  
For WGS in this study, we used the Illumina MiSeq (Illumina, San Diego, California, 
U.S.A) sequencer, which has a high accuracy and a moderate throughput. A limitation 
of this sequencing method is the relatively short reads (≈2 x 250 bp) that result in 
subsequent genome “gaps”. Presently, the  PacBio RS II (Pacific Biosciences, Menlo 
Park, California, USA) sequencer produces the longest reads with a higher resolution 
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and the possibility of complete closed genomes, but this method has a higher 
individual read rate error and is currently rather expensive.152, 153  
 
5.1.3. MLST 
Multi-locus sequence typing is a method suitable for data exchange between 
laboratories, and for   describing lineages or clonal complexes. However, 
differentiation by MLST does not have enough discriminatory power to compare 
isolates that have undergone microevolution, since only housekeeping genes are 
compared.154 However, due to the standardized implementation of MLST schemes, 
this typing method is reproducible and easily comparable to isolates from other 
origins, which more in-depth methods like single nucleotide polymorphism (SNP) 
typing currently is not.155 In this study, MLST results were sufficient for revealing 
that vast genetic differences exist not only between individuals, but also within an 
individual, with some patients having multiple isolates belonging to different ST’s. 
We found that MLST could divide isolates into two GS similar to previous findings 
by 23S rRNA typing,148 but this genetic distinction was not associated to disease state. 
As exemplified in study III, there are genetic differences between isolates of the same 
ST that could be clinically relevant, and a higher resolution must be implemented in 
order to differentiate such strains. Whole-, core- and accessory genome MLST of our 
isolates is currently ongoing.  
 
Our study indicates that human colonization with different C. concisus strains is 
common. Presently, our knowledge about transmission and duration of C. concisus 
colonization is very limited. While colonization of the human oral cavity suggests 
human to human transmission, C. concisus has also been isolated from domestic 
pets,31, 32 and meat products.33 Multi locus sequence typing to determine genetic 
diversity of isolates from different mammalian species has not been performed, but 
would be interesting in terms of evaluating transmission sources. Similarly, studies 
that evaluate colonization in families living in the same house could provide 
information about transmission, as well as longitudinal studies investigating 
colonization in individuals. 
 
 
5.1.4. Detection of virulence genes 
In study III, we investigated the prevalence of two virulence associated genes that 
have previously been described as potentially pathogenic. The zot gene, encoding a 
toxin capable of destructing tight junctions, and exotoxin 9, associated to enhanced 
intracellular survival.149 While we found no association to clinical presentation or 
sampling site for either gene, there was a genetic difference between isolates with 
exotoxin 9 and isolates with zot, with significant grouping into different GS. It was 
apparent that individuals could have isolates with different, or both virulence genes, 
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possibly explained by genetic exchange between isolates. We chose to examine these 
two putative virulence factors, since isolates with these genes have been associated to 
IBD and have shown to have pathogenic effects in-vitro.85, 149 However, other genes, 
such as those encoding CRISPR-associated proteins,74 or the sodium-hydrogen 
antiporter NhaC73 have also been proposed to be associated to virulence in C. 
concisus, but these were not investigated in our present studies.  
The genetic diversity of C. concisus has in part previously been explained by 
variations in genes encoding respiration pathways, peptidoglycan surface structures 
and flagellin glycosylation pathways.72, 73 However, studies that examine genomic 
rearrangements or DNA exchange between strains are lacking. Evolution of bacterial 
pathogens within an individual is common, and has been described for other 
pathogens.156 One of the factors that enables bacterial adaption in a host is phase 
variation (PV), the ability for bacteria to switch gene expression on and off by 
insertion or deletion of polyG or polyC repeat tracts located in the reading frames of 
genes during replication.157  This has been described in detail for C. jejuni, in which 
most PV genes encode enzymes or surface proteins that can modify surface 
structures,157 but this phenomenon has not been investigated in C. concisus. There is 
also very little description of horizontal gene transfer, or natural transformation in C. 
concisus. Natural transformation has been described for many bacterial species, and 
is also shown to occur independently of environmental influences in C. jejuni,158 and 
is an important method for acquisition of resistance genes in bacteria. Chung and 
colleagues recently described the presence of a T4SS system, used to transport large 
molecules across cell membranes, in the genome of an enteric C. concisus strain. The 
system was not present in the oral strain from the same person, indicating that plasmid 
conjugation or gene transfer had occured.74  
 
 
5.2. Main conclusions 
We found that there was a high prevalence of viable C. concisus isolates in clinical 
samples from both IBD patients and healthy individuals. Campylobacter concisus was 
abundant in saliva, faecal samples as well as mucosal biopsies, indicating that 
colonization may be more extensive than previously assumed, and certainly is not 
restricted to the oral cavity. In our study, we included a unique group of IBD patients 
with previous UC-IPAA surgery. Patients with UC-IPAA have a history of severe UC, 
and had more clinical symptoms at the time of biopsy sampling than the other IBD 
groups in this study. When assessing the number of positive biopsies in total, there 
was a significantly higher prevalence of C. concisus in biopsies from UC-IPAA 
patients, compared to the other IBD groups and HC, which had similar prevalence 
rates. When assessing the number of patients that were positive in at least one biopsy, 
there was no difference between groups. This could indicate that it may be bacterial 
abundance, rather than bacterial presence, that contributes to inflammation. 
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By MLST analysis of C. concisus isolates from different patients and various 
locations, we confirmed previous findings of vast genetic diversity. While some 
patients were colonized with only one strain, others had several different strains, 
which did not correlate to clinical presentation. We showed that even isolates from 
the same gut mucosal biopsy could be genetically different, a finding previously only 
described for oral isolates.  
MLST analysis did not reveal a correlation between certain C. concisus isolates and 
clinical presentation, indicating, similar to the findings in study I, that a possible 
association to disease could be related to relative quantities of C. concisus, instead of 
specific GS. Interestingly, there was an association to the site of sampling, with 
significantly more isolates from mucosal biopsies in GS II and oral isolates in GS I, 
however with no correlation to clinical presentation. 
Our collection of Danish C. concisus isolates consisted mostly of gut mucosal isolates. 
We found a high prevalence of the putative virulence gene exotoxin 9, used as a proxy 
for the UNSWCD plasmid with four genes previously described only in isolates from 
patients with gastrointestinal disease. The prevalence of zot was considerably lower 
when comparing to previous findings from Australian oral isolates. Interestingly, the 
polymorphisms of the zot gene described in Australian isolates was not prevalent in 
our collection, possibly indicating variations between different sampling sites or 
maybe between the geographical origin of isolates. While we did not find any 
associations between virulence determinants and disease phenotype, these results 
should be interpreted with caution, since gene expression was not examined.  
 
5.3. Clinical implications 
Isolation of single microbial organisms in relation to infectious diseases has become 
the fundament for understanding mechanisms of microbial pathogenic activity in 
relation to disease evolvement, since the introduction of Koch’s postulates in 1890.159 
However as previously mentioned, the current understanding of chronic inflammatory 
bowel disease is that the etiology is multifactorial and complex, and that the gut 
microbiota as a whole plays an important part.17 Whole genome sequencing 
technologies have provided a greater understanding of the human microbiome, and 
the modulations that can occur over time.5, 6, 13 The microbiota of individuals with 
different C. concisus colonization status has not been investigated, but would be of 
great importance in recognizing the possible effects of other microbial species in the 
pathogenic capacity of C. concisus.  
In a longitudinal study of five children with CD, Kaakoush et al. described an 
association between C. concisus and certain Firmicutes taxa (Faecalibacterium and 
Lachnospiraceae incertae sedis), since levels of these bacterial species in- and 
decreased symbiotically.76 From the same clinical specimens, Kaakoush et al. 
described that abundance of the genera Dialister and Oscillospira were found to 
60 
correlate with higher levels of zot and Exotoxin 9 in CD children with C. concisus 
DNA in stool.81, 160 Similarly to C. concisus, Dialister invisus is an oral bacterium that 
has been associated to periodontitis.34, 161 Interestingly, in the description of the 
dysbiotic environment in CD, decreased levels of Dialister invisus have previously 
been associated to disease,162 while Oscillospira spp. have been detected in increased 
levels in the submucosa of CD patients compared to controls.16 The results from our 
studies indicate that a high abundance of C. concisus could be implicated in disease; 
it is conceivable that C. concisus has pathogenic capabilities that contribute to 
inflammation when the environmental circumstances allow it. Such circumstances 
could be deficient bacterial clearance, alterations in the epithelial mucus layer, or 
enriched availability of carbon sources through the metabolism of other 
microorganisms or metabolites from such organisms.163 Studies that examine the 
effects of C. concisus in both symbiotic and dysbiotic gut microbiotas are warranted 
in order to further establish possible clinical implications of colonization.  
Finally, the antibiotic susceptibility of C. concisus has been sparsely described. 
Vandenberg et al. tested 20 clinical C. concisus isolates from diarrheal stool samples 
(along with other non-jejuni/non-coli Campylobacter species) and found that 5% were 
resistant to erythromycin and ciprofloxacin,164 which are antibiotic regimens 
commonly used in the treatment of diarrhea. In a large study from of 441 clinical 
samples from patients with gastroenteritis from Aalborg, 16% of isolates were 
resistant to ciprofloxacin whereas macrolide resistance was very low.30 In the five 
children with CD studied by Kaakoush et al, treatment with immune modulating drugs 
and antibiotics changed C. concisus colonization status, but the results were 
inconsistent and not related to inflammatory symptoms.76 The results from our studies 
indicate that viable and potentially pathogenic C. concisus exist in the gastrointestinal 
tract of both healthy and diseased individuals. Therefore, the detection of C. concisus 
in a clinical sample should be interpreted with caution, and not necessarily indicate 
antibiotic treatment.  
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CHAPTER 6. PERSPECTIVES 
Although we found that C. concisus could be isolated from healthy individuals, 
previous demonstrations of the pathogenic potential of this bacteria should still 
sanction further investigations into possible associations to gastrointestinal disease. 
There are some accounts for possible associations to other gastrointestinal diseases 
such as microscopic colitis46 – a subtype of IBD characterized by prolonged periods 
of diarrhea and inflammatory cell intrusion of the gut epithelium, without 
macroscopic evidence of inflammation.165 The prevalence of C. concisus in 
esophageal conditions such as GERD, Barrett’s esophagus and EAC49 also warrant 
further investigations into a possible association to these diseases. Recent, interesting 
findings in dysbiosis of the esophageal flora indicate that microbial dysbiosis may 
also be implicated in diseases of the upper gastrointestinal tract.166 
Other molecular technologies are becoming increasingly available and automatized 
for routine use in clinical laboratories. While genomics provides us with detailed 
information about the genetic composition of bacteria, other “omics” should be 
included in order to truly comprehend the virulence of a pathogen. Transcriptomics is 
the measurement of mRNA in a cell, and can be described as a snapshot of gene 
expression. The most common method used for this is high throughput RNA 
sequencing (RNA-seq).83 RNA-seq could elucidate whether or not a specific condition 
is required for expression of certain potential virulence genes, for example; if zot is 
expressed in the absence of inflammation. In proteomics, the quantity of expressed 
proteins are measured, and in metabolomics the metabolic state of an organism is 
evaluated by the total production of small molecules. All of these methods can provide 
valuable information about the pathogenic actions of bacteria and the dynamic 
interactions of bacteria in complex microbial communities.167 
In conclusion, while our studies have provided insights into the abundance and genetic 
diversity of C. concisus in humans, there are many outstanding questions that still 
remain unanswered. Ongoing genetic investigation and experimental studies will 
hopefully expand our understanding of the enigmatic C. concisus, for which the terms 
commensal and pathogen both seem inadequate. 
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6.1. Additional publications and ongoing studies 
Kirk KF, Nielsen HL, Nielsen H. The susceptibility of Campylobacter concisus to the 
bactericidal effects of normal human serum, APMIS. 2015;123:269-74 
 
Ovesen S., Kirk KF, Nielsen HL, Nielsen H. Motility of Campylobacter concisus 
isolated from saliva,   faeces and gut mucosal biopsies,  APMIS 2016. In press. 
Nielsen HL, Kirk KF, Bodilsen J, Ejlertsen T, Nielsen H. Azithromycin vs. placebo 
for the clinical outcome in Campylobacter concisus diarrhea in adults: A randomized, 
double-blinded, placebo-controlled clinical trial. PLoS One. 2016 Nov 
28;11:e0166395 
Ongoing studies:  
Whole-genome characterization of the C. concisus core- and pan-genome  
Microbiota profiling of C. concisus positive IBD patients and healthy controls  
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Appendix B. Protocol for cultivation of 
C. concisus from different locations 
Materials: 
Agarplates: 5% blood agar plates with added yeast extract  
Polycarbonate filters (47 mm diameter, 6 µm pore size) 
10µl inoculation loops  
2 ml Eppendorf tubes  
Sterile saline 
Cotton tip swabs 
 
Incubation conditions:  
Microaerobic (MA): 80% N2, 10% CO2, 5% H2, 6% O2  
Anaerobic (A): 80% N2, 10% CO2, 10% H2 
 
Protocol:  
 
1) Collection of samples (transport to lab immediately after collection):  
a. Biopsies are collected with sterile forceps and placed in sterile 
containers with 0.5 ml sterile saline.  
b. Stool samples are collected in dry containers by participants and 
sent by mail to the laboratory. 
c. Saliva samples are collected in dry, sterile containers on the day of 
colonoscopy.  
 
2) Protocol for faecal samples:  
a. Homogenize faecal sample by mixing with sterile saline1:1.  
b. Mount 4-5 drops of emulsion to polycarbonate filter on 5% blood 
agar with yeast extract. 
c. Incubate for 1 hour at room temperature 
d. Remove filter with sterile forceps. 
e. Incubate for 96 hours in MA atmosphere.  
f. Inspect plates daily – colonies that resemble Campylobacter spp. 
Are inspected by 
i. Wet-mount microscopy 
ii. MALDI-TOF analysis  
iii. qPCR analysis (primers Conc Fmod and Cons R2)  
 
3) Protocol for saliva samples:  
a. Collect saliva on a cotton swab and streak onto agarplate, covering 
the entire surface.  
b. Place 2 x Vancomycin tablets (5 mg) on the agar plate.  
c. Incubate in MA atmosphere for 2 days.  
APP 
d. Collect bacterial mass from 5 mm zone around vancomycin tablets 
and liquefy in Eppendorf tube with 50 µl sterile saline.  
e. Follow steps 2b-2f.  
 
4) Protocol for biopsies:  
a. Biopsies are smeared onto 2 agar plates using inoculation loops. 
b. One plate is incubated for 48 hours in MA, the other in A 
atmospheres. 
c. Following 48 hours of incubation: harvest approximately 100 µg 
bacterial mass by streaking across the agar plates with inoculation 
loop. 
d. Place bacterial mass in Eppendorf tube and add 50 µl sterile saline 
– vortex briefly.  
e. Follow steps 2b-2f.   
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Appendix C. Protocol for PCR for 
detection of C. concisus DNA in 
mucosal biopsies 
 
1) Preparation of DNA from gut mucosal biopsies:  
a. Place biopsy in 1.5 mL Eppendorf tube and add 500 µL sterile saline 
and 1 stainless steel bead (Qiagen)  
b. Homogenize in Tissue Lyser for 2 min. at 20 Hz according to 
instructions 
 
2) DNA extraction (EasyMaG Nuclisens, BioMeriuex)  
a. Extraction as per on-board protocol A to final eluate of 110 µL.  
b. DNA is stored at -20 °C until used for PCR analysis.  
 
3) Preparation for bacterial 16S rRNA gene PCR:  
a. Materials: SYBR green Mastermix (x2), F and R primers, template 
DNA, sterile saline in the following mix in a 96 well PCR plate:  
Reagent Volume 
SYBR Green Mastermix (x2) 12.5 µL 
Forward primer (F27) 1 µL 
Reverse Primer (R1494) 1 µL 
Template DNA  2 µL 
Sterile H2O 8.5 µL 
Total 25 µL 
Primer conc.: 10µM x 1 µL=25µL x 0.4 µM=400 nM 
Remember to account for positive and negative controls and “waste”. 
 
4) Centrifuge 96 well plate for 1 min at 3000 rpm before PCR.  
 
5) PCR is conducted using real-time qPCR (7500 Applied Biosystems) with the 
following conditions: 
Primer Start Dissociation Annealing Elongation Cycles 
16S rRNA 
(bacterial) 
95°C, 10 min 95°C, 20 sec.  63°C, 20 sec. 72°C, 1 min.  35 
C. concisus 95°C, 10 min 95°C, 30 sec. 60°C, 30 sec. 72°C, 30 sec. 40 
 
6) Verification of product size:  
a. Run 96 well plate on QiaExcel Advanced Screen Gel:  
APP 
i. Add 15 µl dilution buffer to empty wells. 
ii. Add 10 µl size marker (mastermix: 25µl SYBR green, 35µl 
sterile saline and 30 µl size marker) 
iii. Add alignment markers (15µl) to single cartridge 
iv. Run using profile “DEC” 
 
7) PCR product purification:  
a. Use Qiagen purification kit according to instructions.  
 
8) PCR for C. concisus 16S rRNA gene 
a. Materials: SYBR green Mastermix (x2), F and R primers, template 
DNA, sterile saline in the following mix in a 96 well PCR plate:  
Reagent Volume 
SYBR Green Mastermix (x2) 12.5 µL 
Forward primer (ConcFmod) 1.25 µL 
Reverse Primer (Conc R2) 1.25 µL 
Template DNA  5 µL 
Sterile H2O 5 µL 
Total 25 µL 
Primer conc.: 10µM x 1 µL=25µL x 0.4 µM=400 nM 
Remember to account for positive and negative controls and “waste” 
 
9) Repeat steps 4 – 6 for PCR and product size verification. 
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Appendix D. Isolates used for WGS  
ID Group Age Sex Isolate ID Source Location (of biopsy) 
3UC UC 44 M AAUH-3UCce Biopsy Cecum 
AAUH-3UCce2 Biopsy Cecum 2 
4UC UC 33 F AAUH-4UCti Biopsy Terminal ileum 
AAUH-4UCti-a Biopsy Terminal ileum  
5CD CD 24 M AAUH-5CDo Saliva  
7UC UC-IPAA 51 F AAUH-7UCil Biopsy Ileum 
8UC UC-IPAA 41 M AAUH-8UCo Saliva  
AAUH-8UCpp Biopsy Proximal pouch 
AAUH-8UCpp-a Biopsy Proximal pouch 
9UC UC-IPAA 45 M AAUH-9UCpp Biopsy Proximal pouch 
AAUH-9UCdp Biopsy Distal pouch 
10UC UC-IPAA 46  M AAUH-10UCf2 Faeces  
AAUH-10UCil-a Biopsy Ileum 
11UC UC 63 F AAUH-11UCco Saliva  
AAUH-11UCdes-a Biopsy Descending colon 
AAUH-11UCsig-a Biopsy Sigmoideum 
12CD CD 63 F AAUH-12CDo Saliva  
AAUH-12CDti2-a Biopsy Terminal ileum 2 
AAUH-12CDti4-a Biopsy Terminal ileum 4 
AAUH-12CDti5-a Biopsy Terminal ileum 5 
AAUH-12CDce Biopsy Cecum 
AAUH-12CDtra-a Biopsy Transverse colon 
AAUH-12CDtra2-a Biopsy Transverse colon 2 
AAUH-12CDdes2 Biopsy Descending colon 2 
AAUH-12CDdes3 Biopsy Descending colon 3 
AAUH-12CDdes4 Biopsy Descending colon 4 
AAUH-12CDsig Biopsy Sigmoideum 
AAUH-12CDrec-a Biopsy Rectum 
15UC UC-IPAA 28 M AAUH-15UCpp Biopsy Proximal pouch 
AAUH-15UCdp Biopsy Distal pouch 
AAUH-15UCdp-a Biopsy Distal pouch 
16UC UC-IPAA 48 F AAUH-16UCo-a Saliva  
AAUH-16UCdp Biopsy Distal pouch  
AAUH-16UCdp3 Biopsy Distal pouch 3 
AAUH-16UCdp5 Biopsy Distal pouch 5 
AAUH-16UCf Faeces  
AAUH-16UCf2 Faeces  
AAUH-16UCf3 Faeces  
20UC UC-IPAA 56 F AAUH-20UCco Saliva  
AAUH-20UCf Faeces  
22UC UC-IPAA 44 M AAUH-22UCpp-a Biopsy Proximal pouch 
35UC UC-IPAA 23 F AAUH-35UCil-a Biopsy Ileum 
AAUH-35UCil2-a Biopsy Ileum 2 
AAUH-35UCil3-a Biopsy Ileum 3 
AAUH-35UCil4-a Biopsy Ileum 4 
AAUH-35UCpp Biopsy Proximal pouch 
AAUH-35UCdp Biopsy Distal pouch 
AAUH-35UCf Faeces  
37UC UC-IPAA 49 M AAUH-37UCo-a Saliva  
AAUH-37UCf Faeces  
39CD CD 30 M AAUH-39CDti-a Biopsy Terminal ileum 
AAUH-39CDrec-a Biopsy Rectum 
AAUH-39CDf Faeces  
40UC UC 51 M AAUH-40UCf Faeces  
43UC UC 67 F AAUH-43UCce-a Biopsy Cecum 
AAUH-43UCf Faeces  
44UC UC 36 M AAUH-44UCsig-a Biopsy Sigmoideum 
AAUH-44UCsig6 Biopsy Sigmoideum 6 
47UC UC-IPAA 38 F AAUH-47UCil Biopsy Ileum 
AAUH-47UCil-a Biopsy Ileum 
48UC UC-IPAA 21 M AAUH-48UCo-a Saliva  
AAUH-48UCil-a Biopsy Ileum 
AAUH-48UCdp-a Biopsy Distal pouch 
49UC UC-IPAA 38 F AAUH-49UCil-a Biopsy Ileum 
AAUH-49UCpp-a Biopsy Proximal pouch 
AAUH-49UCf Faeces Faeces 
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51UC UC-IPAA 41 M AAUH-51UCf Faeces  
55UC UC 57 F AAUH-55UCtra-a Biopsy Transverse colon 
58UC UC 68 F AAUH-58UCo Saliva  
59UC UC-IPAA 42 M AAUH-59UCpp-a Biopsy Proximal pouch 
2HC HC 73 M AAUH-2HCtra Biopsy Transverse colon 
3HC HC 44 M AAUH-3HCo Saliva  
AAUH-3HCce2 Biopsy Cecum 2 
6HC HC 66 M AAUH-6HCo-a Saliva  
8HC HC 45 F AAUH-8HCo Saliva  
AAUH-8HCo-a Saliva  
9HC HC 57 M AAUH-9HCce Biopsy Cecum 
AAUH-9HCasc Biopsy Ascending colon 
10HC HC 63 F AAUH-10HCce Biopsy Cecum 
AAUH-10HCdes Biopsy Descending colon 
AAUH-10HCdes2 Biopsy Descending colon 2 
AAUH-10HCdes3 Biopsy Descending colon 3 
AAUH-10HCdes4 Biopsy Descending colon 4 
AAUH-10HCdes5 Biopsy Descending colon 5 
AAUH-10HCdes6 Biopsy Descending colon 6 
AAUH-10HCdes7 Biopsy Descending colon 7 
AAUH-10HCtra Biopsy Transverse colon 
11HC HC 66 F AAUH-11HCf Faeces  
AAUH-11HCo-a Saliva  
12HC HC 56 M AAUH-12HCf Faeces  
14HC HC 69 M AAUH-14HCce Biopsy Cecum 
15HC HC 53 M AAUH-15HCti Biopsy Terminal ileum 
19HC HC 67 F AAUH-19HCf Faeces  
AAUH-19HCf2 Faeces  
20HC HC 49 F AAUH-20HCasc Biopsy  
AAUH-20HCsig-a Biopsy Sigmoideum 
AAUH-20HCrec-a Biopsy Rectum 
1D D 57 F AAUH-1Dce Biopsy Cecum 
AAUH-1Dasc Biopsy Ascending colon 
AAUH-1Dtra Biopsy Transverse colon 
AAUH-2012179281 Faeces * 
20103762
21 
D 65 M AAUH-2010376221 Faeces  
2D D 20  F AAUH-25Df Faeces  
AAUH-25Df3 Faeces ** 
Ref. HC   ATCC 51561 Faeces  
Ref. CD 12 M UNSW3 Biopsy  
Ref. D   UNSW1 Faeces  
Ref. CD   UNSWCD Biopsy  
Ref. D   UNSWCS Faeces  
Ref. D   ATCC 51562 Faeces  
Ref. CD 3 M UNSW2 Biopsy  
Ref. D   13826 Faeces  
Ref. Gingivitis   ATCC 33237 Saliva  
Abbreviations: CD: Crohn’s disease, UC: Ulcerative colitis, UC-IPAA: J-pouch, HC: healthy control, D: 
Diarrhea. Isolate ID’s indicate patient and isolate source. Isolates ending in –a indicate derivation from 
cultivation in anaerobic atmosphere, all others derive from microaerobic incubation. Ref.: reference 
isolates from ncbi.gov. Individual isolates from the same location (i.e. same agar plate) are numerated 
accordingly. Isolates with only numerical IDs derive from previous studies on patients with persistent 
diarrhea.* Isolate from faeces taken 4 years prior to isolates from the current study **Isolate derived from 
different faecal sample taken three months after initial faecal sample and after two weeks treatment with 
ciprofloxacin.  
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Appendix E. Assembled genome data 
and BIGSdb IDs 
 Isolate ID Disease Source Genome size 
(Mbp) 
Contigs N50 GC 
(%) 
BIGSdb ID  
1 AAUH-3UCce UC Biopsy 1.93 44 103045 39.49 5640 
2 AAUH-3UCce2 UC Biopsy 1.93 38 101107 39.5 5645 
3 AAUH-4UCti UC Biopsy 1.98 54 97028 39.26 5633 
4 AAUH-4UCti-a UC Biopsy 1.98 51 97971 39.2 5632 
5 AAUH-5CDo CD Saliva 2.10 183 89584 37.26 5616 
6 AAUH-7UCil UC-IPAA Biopsy 1.98 58 95686 39.44 5634 
7 AAUH-8UCo UC-IPAA Saliva 1.99 41 154956 39.48 5631 
8 AAUH-8UCpp UC-IPAA Biopsy 2.02 3 82883 39.46 5625 
9 AAUH-8UCpp-a UC-IPAA Biopsy 1.87 92 39071 39.66 5657 
10 AAUH-9UCpp UC-IPAA Biopsy 1.82 47 79679 39.64 5625 
11 AAUH-9UCdp UC-IPAA Biopsy 2.00 102 59846 39.46 5662 
12 AAUH-10UCf2 UC-IPAA Faeces 1.99 36 180736 39.59 5618 
13 AAUH-10UCil-a UC-IPAA Biopsy 2.08 103 180889 39.41 5599 
14 AAUH-11UCo UC Saliva 1.89 112 161715 37.46 5651 
15 AAUH-11UCdes-a UC Biopsy 1.91 51 58626 37.3 5650 
16 AAUH-11UCsig-a UC Biopsy 1.99 31 159029 39.48 5629 
17 AAUH-12CDo CD Saliva 1.81 29 197548 37.56 5670 
18 AAUH-12CDti2-a CD Biopsy 1.81 9 934037 37.56 5612 
19 AAUH-12CDti4-a CD Biopsy 1.81 34 83693 37.57 5669 
20 AAUH-12CDti5-a CD Biopsy 1.82 29 187882 37.59 5665 
21 AAUH-12CDce CD Biopsy 1.86 31 483873 37.46 5659 
22 AAUH-12CDtra-a CD Biopsy 1.97 58 63299 39.42 5636 
23 AAUH-12CDtra2-a CD Biopsy 1.81 24 266692 37.59 5664 
24 AAUH-12CDdes2 CD Biopsy 1.85 49 158794 37.53 5661 
25 AAUH-12CDdes3 CD Biopsy 1.81 54 77176 37.64 5613 
26 AAUH-12CDdes4 CD Biopsy 1.85 26 158715 37.46 5660 
27 AAUH-12CDsig CD Biopsy 1.90 20 257808 37.34 5655 
28 AAUH-12CDrec-a CD Biopsy 1.91 52 102065 39.63 5649 
29 AAUH-15UCpp UC-IPAA Biopsy 1.90 36 162832 39.66 5652 
30 AAUH-15UCdp UC-IPAA Biopsy 2.06 57 52907 39.47 5621 
31 AAUH-15UCdp-a UC-IPAA Biopsy 2.03 130 35098 39.51 5617 
32 AAUH-16UCo-a UC-IPAA Saliva 1.88 43 151248 37.68 5656 
33 AAUH-16UCdp UC-IPAA Biopsy 1.92 57 162832 39.69 5646 
34 AAUH-16UCdp3 UC-IPAA Biopsy 1.99 66 64884 39.67 5630 
35 AAUH-16UCdp5 UC-IPAA Biopsy 2.04 39 142542 39.48 5620 
36 AAUH-16UCf UC-IPAA Faeces 1.89 33 392237 37.68 5654 
37 AAUH-16UCf2 UC-IPAA Faeces 1.88 61 64374 37.67 5610 
38 AAUH-16UCf3 UC-IPAA Faeces 1.87 138 21709 37.69 5658 
39 AAUH-20UCo UC-IPAA Saliva 1.81 24 235464 37.58 5667 
40 AAUH-20UCf UC-IPAA Faeces 1.91 81 45189 39.7 5609 
41 AAUH-22UCpp-a UC-IPAA Biopsy 2.02 44 131008 39.58 5598 
42 AAUH-35UCil-a UC-IPAA Biopsy 1.93 55 97085 39.54 5642 
43 AAUH-35UCil2-a UC-IPAA Biopsy 1.93 41 138370 39.52 5647 
44 AAUH-35UCil3-a UC-IPAA Biopsy 1.93 39 97130 39.52 5648 
45 AAUH-35UCil4-a UC-IPAA Biopsy 1.94 61 80285 39.49 5641 
46 AAUH-35UCpp UC-IPAA Biopsy 1.93 40 134251 39.47 5644 
47 AAUH-35UCdp UC-IPAA Biopsy 1.96 70 138943 39.55 5635 
48 AAUH-35UCf UC-IPAA Faeces 1.97 76 87016 39.52 5637 
49 AAUH-37UCo-a UC-IPAA Saliva 1.90 41 89957 37.49 5653 
50 AAUH-37UCf UC-IPAA Faeces 2.00 54 87543 39.52 5623 
51 AAUH-39CDti-a CD Biopsy 1.93 62 120353 39.47 5643 
52 AAUH-39CDrec-a UCD Biopsy 2.01 94 42323 39.38 5626 
53 AAUH-39CDf CD Faeces 1.96 54 136855 39.51 5639 
54 AAUH-40UCf UC Faeces 2.11 178 34887 39.42 5614 
55 AAUH-43UCce-a UC Biopsy 2.01 118 73289 39.76 5619 
56 AAUH-43UCf UC Faeces 1.97 67 62023 39.64 5638 
57 AAUH-44UCsig-a UC Biopsy 2.05 111 54029 39.40 5708 
58 AAUH-44UCsig6 UC Biopsy 2.02 235 16737 39.56 5706 
59 AAUH-47UCil UC-IPAA Biopsy 1.94 69 70435 39.78 5697 
60 AAUH-47UCil-a UC-IPAA Biopsy 1.92 90 42174 39.81 5690 
61 AAUH-48UCo-a UC-IPAA Saliva 1.88 80 45066 37.58 5679 
62 AAUH-48UCil-a UC-IPAA Biopsy 1.97 58 65623 39.70 5699 
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63 AAUH-48UCdp-a UC-IPAA Biopsy 1.94 202 19218 39.78 5695 
64 AAUH-49UCil-a UC-IPAA Biopsy 2.12 160 43381 39.27 5713 
65 AAUH-49UCpp-a UC-IPAA Biopsy 2.1 162 52807 39.59 5712 
66 AAUH-49UCf UC-IPAA Faeces 2.22 118 97148 39.15 5715 
67 AAUH-51UCf UC-IPAA Faeces 1.9 61 100202 37.29 5684 
68 AAUH-55UCtra-a UC Biopsy 1.88 88 37875 37.43 5677 
69 AAUH-58UCo UC Saliva 2.02 105 34563 39.47 5705 
70 AAUH-59UCpp-a UC-IPAA Biopsy 1.92 49 102305 39.62 5691 
71 AAUH-2HCtra HC Biopsy 1.99 84 52482 39.42 5703 
72 AAUH-3HCo HC Saliva 2.03 336 26870 37.93 5711 
73 AAUH-3HCce2 HC Biopsy 2.07 328 33756 39.88 5714 
74 AAUH-6HCo-a HC Saliva 1.78 85 32468 37.59 5671 
75 AAUH-8HCo HC Saliva 1.78 146 23267 37.76 5672 
76 AAUH-8HCo-a HC Saliva 1.81 132 25221 37.64 5674 
77 AAUH-9HCce HC Biopsy 1.98 189 21463 39.71 5701 
78 AAUH-9HCasc HC Biopsy 1.80 86 41150 37.68 5673 
79 AAUH-10HCce HC Biopsy 1.94 84 43541 39.61 5693 
80 AAUH-10HCdes HC Biopsy 1.91 55 65110 39.58 5687 
81 AAUH-10HCdes2 HC Biopsy 1.90 79 59463 39.62 5681 
82 AAUH-10HCdes3 HC Biopsy 1.91 59 74769 39.59 5686 
83 AAUH-10HCdes4 HC Biopsy 1.90 90 45360 39.64 5680 
84 AAUH-10HCdes5 HC Biopsy 1.91 84 39333 39.6 5685 
85 AAUH-10HCdes6 HC Biopsy 1.98 102 36601 39.63 5700 
86 AAUH-10HCdes7 HC Biopsy 1.90 74 50724 39.62 5682 
87 AAUH-10HCtra HC Biopsy 1.95 72 60348 39.59 5696 
88 AAUH-11HCf HC Faeces 1.92 229 14154 37.71 5688 
89 AAUH-11HCo-a HC Saliva 1.93 218 14905 37.7 5692 
90 AAUH-12HCf HC Faeces 1.96 161 22427 39.49 5698 
91 AAUH-14HCce HC Biopsy 1.83 157 21790 37.66 5675 
92 AAUH-15HCti HC Biopsy 1.95 129 24790 39.84 5694 
93 AAUH-19HCf HC Faeces 2.01 85 48338 39.51 5704 
94 AAUH-19HCf2 HC Faeces 1.98 155 22062 39.64 5702 
95 AAUH-20HCasc HC Biopsy 2.04 319 20031 39.81 5710 
96 AAUH-20HCsig-a HC Biopsy 2.04 152 33006 39.43 5709 
97 AAUH-20HCrec-a HC Biopsy 2.00 82 84768 39.31 5707 
98 AAUH-1Dce-a D Biopsy 2.2 356 48282 39.56 5716 
99 AAUH-1Dasc D Biopsy 1.88 234 13858 39.77 5678 
100 AAUH-1Dtra D Biopsy 1.91 93 39458 39.56 5683 
101 AAUH-2012179281 D Faeces 1.92 34 138913 37.35 5689 
102 AAUH-2010376221 D Faeces 1.85 84 48012 37.67 5676 
103 AAUH-25Df D Faeces 1.81 31 134513 39.74 5666 
104 AAUH-25Df3 D Faeces 2.01 51 121167 39.38 5624 
 ATCC 51561 (ref)       5357* 
 UNSW3 (ref)       5358* 
 UNSW1 (ref)       5359* 
 UNSWCD (ref)       5360* 
 UNSWCS (ref)       5361* 
 ATCC 51562 (ref)       5362* 
 UNSW2 (ref)       5363* 
 13826 (BAA-1457) (ref)       5369* 
 ATCC 33237 (ref)       5398* 
* Corresponding NCBI accession numbers: ATCC 51561= ANNH00000000, UNSW3= 
ANNE00000000, UNSW1= ANNF00000000, UNSWCD= AENQ00000000, UNSWCS= 
ANNG00000000, ATCC 51562= ANNI00000000, UNSW2= ANNJ00000000, 
13826=CP000792.1, CP000793.1, CP000794.1, ATCC 33237= NZ_CP012541.1 
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